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Immune Dysregulation In Pancreatic Cancer 
Abstract 
The clinical success of immune checkpoint blockade (ICB) therapies in recent years has been remarkable. 
Yet most cancer patients, including entire disease types, do not respond to these agents. Pancreatic 
ductal adenocarcinoma (PDAC) is a common and lethal disease that does not respond to ICB treatment. 
Here, we demonstrate that immune dysregulation in the KPC mouse model of PDAC is mediated by a T-
cell priming deficiency that begins in the earliest stages of oncogenesis. Furthermore, we show that 
systemic administration of a CD40 agonist reverses this T-cell priming deficiency. CD40 agonist has been 
shown to drive intratumoral T-cell infiltration and confer ICB-responsiveness to PDAC. This combination 
CD40/ICB therapy depends on CD4+ T-cells in both primary and re-challenge models. We demonstrate 
using single-cell transcriptomics that CD40/ICB therapy depends on the chemokine CCL5, which is 
upregulated across a range of myeloid cells within the tumor. CCL5 mediates the intratumoral influx of 
CD4+ T-cells in response to treatment, and this influx depends upon CCR5. Together, these studies 
describe the immune dysregulation of an ICB-resistant cancer and provide mechanistic insight into a 
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ABSTRACT 
IMMUNE DYSREGULATION IN PANCREATIC CANCER 
Austin Huffman 
Robert H. Vonderheide 
The clinical success of immune checkpoint blockade (ICB) therapies in recent 
years has been remarkable.  Yet most cancer patients, including entire disease types, 
do not respond to these agents.  Pancreatic ductal adenocarcinoma (PDAC) is a 
common and lethal disease that does not respond to ICB treatment.   Here, we 
demonstrate that immune dysregulation in the KPC mouse model of PDAC is mediated 
by a T-cell priming deficiency that begins in the earliest stages of oncogenesis.  
Furthermore, we show that systemic administration of a CD40 agonist reverses this T-
cell priming deficiency.  CD40 agonist has been shown to drive intratumoral T-cell 
infiltration and confer ICB-responsiveness to PDAC.  This combination CD40/ICB 
therapy depends on CD4+ T-cells in both primary and re-challenge models.  We 
demonstrate using single-cell transcriptomics that CD40/ICB therapy depends on the 
chemokine CCL5, which is upregulated across a range of myeloid cells within the tumor.  
CCL5 mediates the intratumoral influx of CD4+ T-cells in response to treatment, and this 
influx depends upon CCR5.  Together, these studies describe the immune dysregulation 
of an ICB-resistant cancer and provide mechanistic insight into a clinically promising 
strategy to reverse that dysregulation.   
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CHAPTER 1 – CANCER IMMUNOLOGY: THE STATE OF THE 
FIELD IN 2020 
A Brief History of Cancer Immunology 
The study of cancer immunology, or our understanding of the interaction between 
the immune system and transformed cells, is often portrayed as a relatively recent 
development.  Certainly, the field is much advanced in recent years, but the initial 
observations that cancer and the immune system interact date back to antiquity.  
Anecdotal observations of spontaneous tumor regression or regression in the context of 
a concomitant infection date back approximately 3,000 years to ancient Egypt1.  Noticing 
similarities between inflammation and cancer, the ancient Greek physician Galen rather 
presciently proposed that cancer could arise from inflammatory lesions during the 
second century AD2.   
Scientifically rigorous study of cancer immunology in the modern era, however, 
began when the 19th century German physicians Busch and Fehleisen performed the 
first documented attempts to experimentally modulate tumor growth by inoculating 
cancer patients with Streptococcus pyogenes, the causative agent of erysipelas3,4.  
Perhaps most famously, the American surgeon William Coley developed “Coley’s Toxin” 
at the turn of the 20th century, a mixture of killed Streptocuccus pyogenes and Serratia 
marcescens to be injected directly into the tumor5.  As there was little mechanistic 
explanation for the efficacy of Coley’s Toxin, his work was considered controversial 
during his lifetime.  The benefit of hindsight, however, has led some today to refer to him 
as the “Father of Immunotherapy.”   
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The observations of Busch, Fehleisen, and Coley could reasonably have been 
expected to spark a burgeoning interest in cancer immunology during the first half of the 
20th century.  Instead, however, oncologists remained focused on the chemotherapies 
and radical surgeries in vogue at the time.  As a result, the next foundational 
developments in cancer immunology did not occur until the late 1950s.  In 1957, the 
same year that Isaacs and Lindenmann described interferon6,7, Thomas and Burnet first 
articulated the theory of Cancer Immunosurveillance8.  They proposed that lymphocytes 
at homeostasis patrolled, identified, and eliminated transformed cells.  In 1959 the 
husband and wife team Ruth and John Graham published a 114-patient cohort study of 
a cancer vaccine made from adjuvanted tumor lysate in patients with gynecologic 
malignancy9.  Incredibly, despite a 22% rate of remission or stable disease, this seminal 
study went largely unnoticed.  The underappreciation of what should have been a pivotal 
observation could perhaps also be attributed to the lack of mechanistic understanding, 
as immunity was largely understood to be a function of antibody at the time10.  This 
would change in short order.   
Nearly all the cellular lineages we understand today to be critical mediators of 
anti-cancer immunity would be described in the span of only a decade starting in the 
mid-1960s.  Jacques Miller described for the first time the role of cellular adaptive 
immunity and T-cells in 196711.  Ralph Steinman discovered and characterized dendritic 
cells (DCs) in 197312 and Eva Klein first described the activity of natural killer (NK) cells 
in 197513,14.  Zinkernagel and Doherty, meanwhile, described major histocompatibility 
complex (MHC) restriction in 197415.  In the same year, Stutman showed that nude mice 
(mice missing critical immune system components) develop cancers at higher rates than 
their wild-type compatriots16.   
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It was also during this period of rapid-fire immunological discovery that bone 
marrow transplantation was being pioneered at the University of Minnesota as a 
treatment for patients with blood malignancies17.  Shortly thereafter physicians at MD 
Anderson Cancer Center began treating chronic myeloid leukemia (CML) patients with 
recombinant interferon-alpha18.  In 1976 the benefit of treating superficial bladder cancer 
patients with Bacillus Calmette-Guerin (BCG), a therapeutic strategy still used today, 
was first demonstrated19.  While an appreciation of the potential for significant interplay 
between the immune system and cancer grew during this period, lack of mechanistic 
explanation yet again stymied a broader acceptance in the field. 
This need for a definitive mechanistic understanding of the role of the immune 
system in cancer would dog the field until the groundbreaking work of Robert Schreiber’s 
group at the turn of the 21st century.  Schreiber and colleagues finally documented 
irrefutable evidence that T-cells and interferon-gamma mediated immune surveillance of 
transformed cells, anti-tumor immune responses, and immune-mediated escape20.  
Schreiber’s group proposed a revision to the cancer immunosurveillance hypothesis they 
called immunoediting.  They demonstrated that at baseline the immune system 
(predominately through T-cells and interferon-gamma) likely surveil the organism and kill 
transformed cells as they arise.  Over time, however, this immune pressure selects for 
minimally immunogenic cancers cells, giving rise to tumors that evade immune 
clearance and eventually grow out into the clinical presentation of cancer.  This at once 
reconciled the observations that the immune system could be an effective tumor 
suppressor but that cancers could arise in otherwise immunocompetent hosts.  This new 
model set the stage for a series of studies describing the pathways by which tumors 
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evade immune clearance, as well as the development of therapeutics blocking or 
reversing those pathways in order to drive anti-tumor immunity.   
The two most notable of these pathways, cytotoxic T-lymphocyte antigen 4 
(CTLA-4) and programmed death 1 (PD-1), began to be elucidated around the same 
time as Schreiber and colleagues made their observations.  CTLA-4 was first discovered 
by Brunet and colleagues in 198821 but its role as a negative regulator of T-cell function 
was not fully understood until Jim Allison’s group elucidated it in 199522.  Its potential as 
an anti-cancer agent was immediately appreciated and demonstrated in animal models a 
year later23.  Clinical trials testing antibodies that blocked CTLA-4 were initiated shortly 
thereafter and in 2011 ipilimumab became the first FDA-approved checkpoint inhibitor 
for treatment of late-stage melanoma patients24.   
Similarly, PD-1 was first identified in 1992 by Tasuku Honjo’s group25.  Honjo’s 
group also demonstrated in 1999 that PD-1 deficient mice were prone to autoimmunity, 
concluding that PD-1 negatively regulated the immune system26.  PD-1 blocking agents 
were quickly developed and tested in clinical trials and nivolumab was first approved by 
the FDA in 201427.  Today, multiple immune checkpoint blockade (ICB) therapeutic 
antibodies targeting components in the CTLA-4 and PD-1 pathways are approved 
across a broad range of cancers28.  With long term survival approaching 50% in some 
trials these cancer immunotherapies have saved thousands of lives and transformed the 
standard of care in many cancers.  As a result, the 2018 Nobel Prize in Physiology and 
Medicine was jointly awarded to Jim Allison and Tasuku Honjo for their groundbreaking 




The Basic Biology and Mechanisms of Immune Checkpoint Blockade 
CTLA-4 is an immunoglobulin superfamily receptor that is upregulated on T-cells 
immediately after T-cell receptor (TCR) stimulation.  First characterized as a negative 
regulator of T-cell activity, it was soon recognized that CTLA-4 acts in direct opposition 
to the costimulatory molecule CD2822,29.  This activity is made possible by CTLA-4’s 
higher avidity and affinity for their shared binding partners CD80 (B7-1) and CD86 (B7-
2), which are expressed on professional antigen presenting cells (APCs).  This causes 
the inhibitory molecule to outcompete the costimulatory molecule, attenuating T-cell 
activation30–33.  The expression kinetics of CTLA-4 and the fact that it acts in direct 
opposition to CD28 costimulation dictate that its negative effect on T-cell activity occurs 
primarily during the priming phase of adaptive immunity.  Accordingly, genetic ablation of 
murine Ctla4 causes a massive lymphoproliferative disorder that is lethal within a month 
of birth34,35.  Beyond this core activity in the priming phase CTLA-4 also likely mediates 
regulatory function in activated T-cells in peripheral tissues, given the expression of its 
ligands on APCs in that environment.   
CTLA-4 is also highly expressed on T-regulatory cells (T-regs), and in fact 
genetic loss of T-reg-specific CTLA-4 gives rise to autoimmunity36,37.  On the surface this 
seems a paradox, unless T-reg CTLA-4 acts in a cell-extrinsic manner, potentially acting 
as a sink for costimulatory molecules at a population level.  For example, CTLA-4 has 
also been shown to trans-endocytose CD80 and CD86 from antigen presenting cells, 
negatively regulating costimulatory capacity in a cell-extrinsic – and therefore potentially 
antigen-independent – manner38.  Recently, however, Arlene Sharpe’s group 
demonstrated that if T-reg CTLA-4 is instead deleted in adulthood resistance to 
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autoimmunity is conferred39.  While additional studies are clearly needed, it seems likely 
that the role of T-reg CTLA-4 is context-dependent.   
The mechanisms of CTLA-4 blockade as an anti-cancer therapy largely mirror 
the functions of the molecule at homeostasis.  The core benefit is thought to be derived 
from the prevention of CTLA-4 from outcompeting CD28 for the costimulatory ligands 
CD80 and CD86, boosting the T-cell priming process28.  Accordingly, the benefit is 
thought to be localized mainly in the tumor-draining lymph nodes and potentially in 
tertiary lymphoid structures where priming occurs.  Additional evidence for a primarily 
localized, priming-oriented mechanism of action can be found in the observation that 
CTLA-4 blockade leads to an expansion of neoantigen-specific T-cells within the tumor, 
but not in the secondary lymphoid organs40.  An interpretation of this observation is that 
priming of T-cells against tumor neoantigens occurs at baseline and that CTLA-4 
blockade amplifies this process, without having a generalized effect on all T-cells.   
The effect of CTLA-4 blockade on T-regs is a source of significant debate and 
ongoing research.  It is established that CTLA-4 blockade results in the depletion of T-
regs resulting in tumor rejection in mice41–43.  T-reg depletion appears to occur 
disproportionately in the tumor over the periphery, potentially a function of higher CTLA-
4 expression on intratumoral T-regs or the high local abundance of tumor-associated 
macrophages which express Fcγ-receptors42.  The degree to which this mechanism 
mediates efficacy remains unclear, however.  At least one study attributes the entire 
efficacy of CTLA-4 blockade to T-reg depletion44, but this finding conflicts with other lines 
of evidence.  First, significant anti-tumor efficacy was still seen in FcγRIV knockout 
mice41.  Second, blockade of CTLA-4 is required on both effector T-cells and T-regs for 
effective anti-cancer efficacy45.   
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Much less is known about the relative contribution of CTLA-4-B7-ligand 
disruption versus T-reg depletion in humans, but ipilimumab specifically binds to the B7-
binding domain of CTLA-4, highly implicating steric hindrance of that interaction46.  Ex 
vivo evidence does suggest ipilimumab is capable of inducing antibody-dependent 
cellular cytotoxicity (ADCC) against T-regs47.   Additionally, a polymorphism that 
increases affinity of an Fc receptor is positively predictive of ipilimumab response48.  
When one compares the efficacy of ipilimumab (an IgG1 antibody) and tremilimumab (an 
IgG2 antibody), however, the two anti-CTLA-4 drugs have relatively comparable efficacy 
in pooled analyses49,50.  This underlines the likely primacy of the CTLA-4-B7-ligand 
disruption mechanism, although both mechanisms clearly contribute in various contexts 
and further study is warranted.   
PD-1 is an inhibitory immunoglobulin superfamily receptor expressed on 
activated T-cells.  Its ligands are PD-L1 and PD-L2 are widely expressed in response to 
inflammatory cytokines, most notably IFNγ51,52.  This expression pattern dictates that 
PD-1 acts mainly to restrain effector T-cell activity in the periphery53.  At homeostasis, 
PD-1 is necessary to maintain peripheral tolerance, as illustrated by studies of genetic 
Pdcd1 loss resulting in strain-variable autoimmunity54,55.  Blockade of PD-1, therefore, 
has obvious attraction as an anti-cancer therapy.   
The mechanism of PD-1 blockade anti-cancer efficacy reflects the molecule’s 
role at homeostasis, reinvigorating T-cells in peripheral tissues – particularly within the 
tumor itself.  PD-1 blockade appears to enhance the activity of neoantigen-specific T-
cells56, although the relatively common autoimmune side effects of these agents 
suggests significant non-tumor-specific activation also occurs57.  Much of the focus on 
the effects of PD-1 blockade on T-cells to date has focused on CD8+ T-cells58,59.  Much 
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understudied, however, are CD4+ T-cells, which are also required for efficacy60.  Other 
potentially understudied areas are the effects of PD-1 blockade on tumor cells 
themselves as well as intratumoral myeloid cells61,62.   
PD-L1 blockade strategies have also proven effective anti-cancer agents and are 
thought to largely phenocopy PD-1 blockade, given the predominance of PD-L1 as a 
ligand in the context of cancer63.  Given that tumor cells themselves as well as certain 
immunosuppressive intratumoral myeloid populations can express PD-L1, however, 
ADCC may play a role in anti-PD-L1 therapeutic efficacy.  Fc-receptor sufficiency was 
shown to mediate the anti-PD-L1-induced, but not anti-PD-1-induced, tumor regressions 
in a mouse model of colon cancer64.   
The combination of PD-1 and CTLA-4 blockade leads to superior outcomes 
compared to either alone65.  Whether the enhanced efficacy of the combination therapy 
is due to additive or complementary mechanisms remains an open question in the field, 
but early evidence in patient immunoprofiling points to distinct responses40,66.  Further 
studies are necessary to determine the relative contributions of each agent and the 
mechanistic basis, with implications ranging from sequence of administration to rational 




The Next Generation of Cancer Immunotherapies 
Producing durable long-term remissions and cures in a subset of patients, ICB 
has quickly become standard of care in common and deadly diseases like melanoma 
and lung cancer28.  While this represents a significant advance in cancer therapy the 
sobering reality is that only a fraction of patients respond to these agents28,65.  
Determining how to extend these life-saving therapeutic benefits to non-responders, 
therefore, is a high priority for the field.  While analogous strategies targeting other 
inhibitory receptors such as TIGIT, LAG3, and Tim3 have seen some moderate 
success69–71, at this point unearthing another receptor with the clinical impact of PD-1 or 
CTLA-4 seems unlikely.   As a result, strategies today are typically oriented around 
modulating the pathways that determine ICB-responsiveness, with the ultimate goal of 
modulating those pathways in order to potentiate otherwise unresponsive patients to ICB 
agents72–74.  In order to optimize those strategies we first must understand the basic 
biology that determines ICB-responsiveness.   
It is intuitive that PD-L1 expression within the tumor is predictive of response to 
PD-1 inhibition therapy, and indeed several studies have found a such a correlation 75–82.  
Accordingly, PD-L1 expression in the tumor by IHC is used as an FDA-approved 
companion diagnostic tool83.  PD-L1 expression is, however, an imperfect predictor of 
anti-PD-1 therapy response.  Several contradictory studies have found no association 
between PD-L1 expression and therapy response84–87, and many patients exist who 
respond despite minimal detectable PD-L188.  Several potential explanations for this 
variability likely exist, including technical variables such as the use of different assays 
and cutoffs, as well as biological variables such as while cell type PD-L1 is expressed on 
and the limitations of IHC as a temporal snapshot of what is likely a dynamic expression 
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pattern81,89,90.  While further study is warranted, it seems clear that PD-L1 expression 
within the tumor alone is clearly an insufficient explanation for ICB therapy response.     
Patient genetics may also play a role in predicting response to ICB.  Some of the 
earliest evidence for the potential role of genetics came from the variance in 
autoimmune presentation in Pdcd1 knockout mice, which varies based on strain.  
C57BL/6 mice deficient for Pdcd1 develop a lupus-like autoimmune disorder, while 
BALB/c Pdcd1 knockout mice develop an autoimmune dilated cardiomyopathy26,54.  
Additionally, HLA-I heterozygosity has been retrospectively detected as a positive 
predictor of survival in ICB-treated patients, potentially due to the ability to present a 
more diverse repertoire of peptides91.  While patient genetics does not represent a 
particularly actionable lever to improve response to ICB it nevertheless may help predict 
which patients should receive these therapies and in what line of treatment.   
Self-antigens undoubtably contribute to anti-tumor immunity, but the primary 
targets of anti-cancer immunity in many cases are peptides derived from mutations in 
the cancer genome and expressed in a presumably tumor-specific manner, termed 
neoantigens92–100.  Two of the most responsive cancers are melanoma and NSCLC, 
which are often driven by the highly mutagenic effects of UV light and cigarette smoke, 
respectively82,101–103.  In fact, across several malignancies, a history of smoking positively 
predicts response to ICB104.  These initial observations spurred a more systematic 
evaluation of mutation quantity (termed “tumor mutational burden” or TMB) as a 
predictor of ICB response, and TMB was indeed found to positively predict ICB response 
across a range of tumors105.  Concurrently, the FDA granted approval to the anti-PD-1 
therapy pembrolizumab in patients with microsatellite instability-high (MSI-H) or 
mismatch repair deficient (dMMR) tumors, for the first ever time agnostic to the tissue of 
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cancer origin106.  It is hypothesized that these patients respond well to anti-PD-1 therapy 
because MSI-H and dMMR tumors have lost cellular constitutive DNA replication error 
repair machinery, resulting in a high number of mutations107.   
TMB is simply a gross evaluation of the quantity of mutations in a tumor, but not 
all mutations are qualitatively equivalent.  A patient with relatively few mutations that are 
nevertheless highly immunogenic may respond better to ICB than a patient with more 
numerous but less immunogenic mutations.  To determine the contribution of neoantigen 
quality, our group recently developed a prediction algorithm called antigen.garnish108.  
Using this algorithm, we demonstrated that a set of peptides defined primarily by high 
dissimilarity to the self-proteome were more likely to be immunogenic and positively 
predict ICB clinical response.  Our finding supports the hypothesis that overall TMB is a 
crude metric and what matters is the immunogenic quality of those mutations.   
The Tumor Microenvironment as a Predictor of Checkpoint Blockade Therapy Response 
It is intuitive that tumors with evidence of anti-tumor immune activity should be 
more sensitive to ICB therapy, as ICB is thought to act in large part by reinvigorating an 
existing adaptive immune response109–111.  Accordingly, one of the strongest positive 
prognostic indicators is baseline infiltration by T-cells, either at the margins of the tumor 
or within the tumor itself.  This predictive signature includes both CD8+ and CD4+ T-
cells, although the latter is less well understood112–116.  This phenomenon has led to the 
popularization of a “hot” vs “cold” tumor spectrum, wherein “hot” tumors are 
characterized as T-cell inflamed at baseline and responsive to ICB therapy, while “cold” 
tumors are characterized by T-cell paucity and ICB-unresponsiveness(Figure 1-1)117.  
This dichotomy certainly oversimplifies a complex biology – for example are cold tumors 
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actively excluding T-cells through TGFβ or WNT-β-catenin signaling or has an adaptive 
immune response simply failed to be generated? – but it serves as a helpful model118–120.  
The study of “cold” tumors and how to convert them into “hot” tumors – i.e. confer ICB 
responsiveness – is therefore of great interest to the field121.    
Pancreatic ductal adenocarcinoma (PDAC) is perhaps the archetypical “cold” 
tumor type.  PDAC is a common and lethal disease, claiming the lives of 90% of patients 
within five years of diagnosis.  The PDAC tumor is predominantly characterized by a 
paucity of tumor T-cell infiltration, although some heterogeneity does exist122.  
Accordingly, except for the <1% of patients who are MSI-high, ICB has to date shown no 
clinical benefit in PDAC 101,123.  In mice, the spontaneous KPC mouse model (LSL-
KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre) recapitulates the human disease124.  Our 
group has previously published that tumors in KPC mice as well as subcutaneously 
implanted tumors derived from the KPC model are unresponsive to ICB therapy125.  
Understanding the biological determinants of baseline T-cell paucity in PDAC can 
therefore inform translational strategies to drive T-cells into “cold” tumors, potentially 
conferring ICB-responsiveness and extending clinical benefit to that subset of patients – 




The Cancer Immunity Cycle 
In 2013, Chen and Mellman popularized a model called the cancer immunity 
cycle126.  Simply an oncology-centric illustration of adaptive immunity, the cancer 
immunity cycle nevertheless illustrates the discrete steps in anti-tumor immunity (Figure 
1-2).  They posit that tumors cause one or more step to become faulty, allowing immune 
escape.  For example, in “hot” tumors, an anti-tumor immune response has been 
successfully generated but T-cells become dysfunctional within the tumor itself (Figure 
1-2.5) for example through intratumoral PD-L1 overexpression, resulting in tumor 
survival.  This is reversible by the administration of ICB agents that positively regulate T-
cell activity.  The cancer immunity cycle lens can also be applied to the 
immunostimulatory effects of lytic chemotherapies, which increase cancer antigen 
release (Figure 1-2.1) and local danger signals to stimulate their presentation (Figure 1-
2.2).  Applying this model to “cold” tumors, one may hypothesize that ICB-resistant 
tumors have derailed the cancer immunity cycle by inducing deficiencies in antigen 
presentation and priming, T-cell trafficking and infiltration, or both.  Understanding how 
these processes occur in PDAC and developing strategies to reverse deficiencies is 




CD40 Agonist Immunotherapy 
The TNF superfamily member CD40 is expressed predominantly on the surface 
of DCs, B-cells, and myeloid lineages127.  Activation through the CD40 receptor confers 
cellular maturation upon ligation with CD40 ligand (CD40L), which is classically 
expressed on activated CD4+ T-cells128.  This maturation is referred to as licensing and 
results in the upregulation of the costimulatory molecules CD80 and CD86, as well as 
the Th1-polarizing cytokine IL-12 and a number of T-cell activating TNF family members 
including OX40, GITR, and 41BB129–131.  The positive stimulation of this pathway, 
therefore, massively upregulates APC function.  This highly proximal positioning in a 
critical adaptive immunity signaling cascade situates agonistic CD40 as a potentially 
unique opportunity for anti-cancer therapeutic interventions.   
Our group has shown that systemically administered agonistic CD40 monoclonal 
antibody (mAb) induces intratumoral T-cell infiltration in a genetic mouse model of 
pancreatic adenocarcinoma and potentiates response to immune checkpoint 
blockade125,132.  This concept has now been taken forward to a national randomized 
clinical trial, which is ongoing (NCT03214250). Preclinically, tumor regressions with 
CD40 mAb require both CD8+ and CD4+ T-cells.  Mice depleted of CD4+ T-cells fail to 
reject implanted pancreatic cancer cell lines despite treatment with CD40 mAb combined 
with chemotherapy, radiotherapy, or immune checkpoint blockade68,132–134.  Furthermore, 
CD4+ but not CD8+ T-cells are required for memory protection against rechallenge in 
mice cured of these tumors, despite the fact that these tumors do not express MHC 
class II132.  This anti-tumor response appears to be driven by a strong upregulation of 
cytokine production by intratumoral CD4+ T-cells in response to the combination of 
CD40 agonist and immune checkpoint blockade132.  Therefore, CD40 agonist-induced 
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tumor immunity is a desirable system in which to study CD4+ tumor immunity.  To 
advance this novel approach to immunotherapy135 – with emerging promising results136–
140 – understanding cellular and molecular effects is increasingly important.   
The CCL5/CCR5 Chemokine Axis, T-cell Trafficking, and Cancer 
The chemokine CCL5, also known as RANTES, is a T-cell chemoattractant that 
has been best described for its critical roles in immune control of viral infections141. The 
role of CCL5 in cancer remains incompletely examined, as it has been associated with 
both anti-tumor and pro-tumor functions including T-regulatory cell attraction, 
progression and metastasis, tumor-associated macrophage function, and the indirect 
modulation of both CD8+ chemoattraction and repulsion142–147.  The best characterized 
receptor for CCL5 is the G protein-coupled receptor CCR5148. Past manipulations of the 
CCL5-CCR5 signaling axis in cancer patients have been dominated by the use of CCR5 
antagonists to mitigate T-regulatory cell and tumor associated macrophage 
infiltration143,149,150.  CCR5 inhibition has also been used in attempts to sensitize tumors 
to chemotherapy and prevent metastasis, and shows promise as a means of preventing 
visceral graft versus host disease in cancer patients after allogenic bone marrow 




Technological Advances Drive Immunological Discovery 
The tumor microenvironment (TME), or the collection of cellular populations 
within the tumor, is a complex and heterogeneous ecosystem that includes the tumor 
cells themselves, fibroblasts, and the immune infiltrate.  The composition of the TME 
varies both across and within diseases and is a critical determinant of response to 
immunotherapy155.  Study of the TME, therefore, requires highly dimensional techniques 
in order to isolate and examine the various cellular lineages and their qualities.  Despite 
impressive recent advances in the dimensionality of flow cytometric techniques, 
including the development of CyTOF, the number of measurable aspects with these 
techniques remain orders of magnitude fewer than the number of potential axes of 
variability (i.e. the number of genes transcribed, translated, and expressed within the 
ecosystem).  Conversely, traditional transcriptomic techniques that can capture the full 
range of variation are limited to average expression within a sample.  Even pre-enriching 
for a population of interest remains limited in that significant heterogeneity within cellular 
lineages exists and is necessarily lost by bulk sequencing techniques156.  Both flow 
cytometric and population-enriched bulk sequencing are also by definition biased by the 
parameters investigators select at the outset of a study.  Until recently, the study of the 
TME was limited by the lack of highly dimensional and unbiased techniques156.   
The recent advent of single-cell transcriptomics, in which transcriptomic data is 
obtained on a cell-by-cell basis, provided an opportunity to address this gap in 
investigational toolset.  Microfluidic systems physically isolate individual cells and 
perform cellular lysis, DNA extraction and amplification, and uniquely barcode on a cell-
by-cell basis.  This heroic engineering effort ultimately results in next-generation 
sequencing (NGS) output where each read can be mapped to an individual cell of origin.  
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This ability to capture variability at the transcriptomic level with the cellular precision of 
flow cytometry has provided unprecedented insights into heterogeneous biological 
systems.  The TME is precisely one such system and single-cell transcriptomics shows 
great promise in advancing our understanding of the cellular populations within the 









Figure 1-1.  “Hot” and “Cold” tumors.     
cDC1 = Type 1 conventional dendritic cell; MDSC = myeloid-derived suppressor cell; T-








Figure 1-2.  The Cancer Immunity Cycle. 
Adapted from Chen and Mellman, Oncology meets immunology: the cancer-immunity 






CHAPTER 2 – CCL5 MEDIATES CD4+ T-CELL TUMOR 
TRAFFICKING AND THERAPEUTIC EFFICACY OF CD40/ICB 
IMMUNOTHERAPY 
 
Parts of this chapter were previously published in: 
 
Huffman AP, Lin JH, Kim SI, Byrne KT, Vonderheide RH.  CCL5 Mediates CD40-Driven 
CD4+ T-cell Tumor Infiltration and Immunity.  JCI Insight, 2020.  doi: 




The first major project in my thesis examined the role of the chemokine CCL5 in 
mediating CD4+ T-cell tumor trafficking and response to combination CD40 agonist and 
immune checkpoint blockade therapy in pancreatic cancer.  Recently published in JCI 
Insight, I was the primary driver of this project and as such it formed the backbone of my 
thesis work during my time in the Vonderheide lab.   
CD4+ T-cells play a critical role in tumor immunity and response to 
immunotherapy, but their mechanisms of action remain incompletely understood60,94,164–
1671–6. Canonical functions such as T-cell help provided to professional antigen-
presenting cells (APCs) during priming and production of anti-tumor cytokines like IFN-γ 
have been well-described168–170.  A recent study demonstrated, however, that 
spontaneous and immunotherapy-mediated anti-tumor responses may require CD4+ T-
cells in addition to CD8+ T-cells, even when tumors lack MHC class II171.  These findings 
recall early preclinical experiments with CTLA-4 monoclonal antibody (mAb) in which 
anti-tumor responses were dependent not only on CD8+ T-cells but CD4+ T-cells as 
23 
 
well166. Since then, CD4+ T-cell-dependency has been observed in many other cancer 
immunotherapeutic approaches60,94,164–167,172–175. In the clinic, major tumor regressions 
have been observed following adoptive transfer of CD4+ (without CD8+) T-cells in 
refractory solid tumors that are unlikely to express MHC class II on cancer cells176,177.  
Therefore, further mechanistic study of CD4+ T-cells in the context of immunotherapy is 
warranted.   
The TNF superfamily member CD40 is expressed on the surface of APCs and 
confers cellular maturation upon ligation with CD40 ligand (CD40L), which is classically 
expressed on activated CD4+ T-cells128.  Our group has shown that systemically 
administered agonistic CD40 monoclonal antibody (mAb) induces intratumoral T-cell 
infiltration and potentiates response to immune checkpoint blockade in a mouse model 
of pancreatic adenocarcinoma125,132.  This concept has now been taken forward to a 
national randomized clinical trial, which is ongoing (NCT03214250). Preclinically, tumor 
regressions with CD40 mAb require both CD8+ and CD4+ T-cells.  Mice depleted of 
CD4+ T-cells fail to reject implanted pancreatic cancer cell lines despite treatment with 
CD40 mAb combined with chemotherapy, radiotherapy, or immune checkpoint 
blockade68,132–134.  Furthermore, CD4+ but not CD8+ T-cells are required for memory 
protection against rechallenge in mice cured of these tumors, despite the fact that these 
tumors do not express MHC class II132.  This anti-tumor response appears to be driven 
by a strong upregulation of cytokine production by intratumoral CD4+ T-cells in response 
to the combination of CD40 agonist and immune checkpoint blockade132.  Therefore, 
CD40 agonist-induced tumor immunity is a desirable system in which to study CD4+ 
tumor immunity.  To advance this novel approach to immunotherapy135 – with emerging 
promising results137–140,178 – understanding cellular and molecular effects is increasingly 
important.   
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It seems clear that chemotaxis of CD4+ T-cells into the tumor microenvironment 
is required for response to immunotherapy, including CD40 agonists, given that 
therapeutic response is lost upon systemic administration of the sphingosine-1-
phosphate receptor antagonist which blocks lymph node egress60.  Several studies have 
been performed in recent years on mechanisms of CD8+ T-cell tumor infiltration, in 
particular implicating the CXCL9/CXCL10/CXCR3 axis, but the extent to which these 
mechanisms do or do not apply to CD4+ T-cell tumor infiltration remain unexplored142,173–
175,179.     
Here, we used single cell sequencing to examine heterogeneous populations in 
our CD40 model in a highly dimensional and unbiased manner180,181.  We discover a 
broad and consistent upregulation of the chemokine CCL5 by intratumoral myeloid 
populations in response to CD40 activation. Blocking the CCL5-CCR5 pathway 
pharmacologically or genetically decreases tumor CD4+ T-cell infiltration in response to 
CD40 agonist immunotherapy, hinders immune control of tumor outgrowth, and shortens 
survival. Our findings suggest a novel critical role for CCL5 in CD4+ T-cell tumor 






Single-Cell RNA Sequencing Identifies Intratumoral Immune Populations 
To investigate the differences in the tumor microenvironment after CD40 agonist 
treatment, we subcutaneously transplanted C57Bl/6J mice with a clonal murine 
pancreatic ductal adenocarcinoma (PDAC) cell line (4226.MD10).  After 14 days of 
tumor growth, tumor-bearing mice were randomized into groups of equal baseline tumor 
size and were treated with an agonist CD40 mAb, immune checkpoint blockade (ICB) 
with CTLA-4 and PD-1 mAb, both CD40 and ICB (hereafter CD40/ICB), or control mAbs 
(Figure 2-1A).  Tumor growth curves comparing CD40/ICB treated mice with untreated 
mice statistically diverged 12 days after the start of treatment (Figure 2-1B).  Day 12 was 
therefore chosen as the optimal timepoint at which to query changes in the immune 
compartment of the tumor following therapy.   
Tumors were harvested and disaggregated on day 12 post-treatment induction.  
Live CD45+ cells were sorted from each tumor for single-cell RNA sequencing using the 
10X Genomics pipeline.  The 10X Genomics platform yielded data for ~5,000 cells per 
treatment condition with an average of ~50,000 reads per cell (Figure 2-6A).  In total 
across all four treatment conditions, 28,348 cells were sequenced.  Fastq files were 
aligned and preprocessed using 10X Genomics’ Cell Ranger software and the Seurat3 R 
package (Figure 2-6B).  To define immune populations within the tumor 
microenvironment, a normalized subset of ~2,000 cells were computationally pooled 
from each treatment group. Graph-based clustering was then used to identify 
transcriptional clusters consisting of individual cell types (Figure 2-1C).  The top 
conserved genes across all treatment groups were identified within each cluster (Figure 
2-1D). Identification of canonical marker genes and comparison with the ImmGen 
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database yielded 11 distinct clusters of immune cell types.  UMAP non-linear 
dimensional reduction revealed three larger meta-clusters containing cells associated 
with distinct immune characteristics: a T-cell meta-cluster containing CD4+ and CD8+ T-
cells, a “pro-tumor myeloid” meta-cluster containing immune suppressive lineages 
including myeloid-derived suppressor cells and granulocytes, and an “anti-tumor 
myeloid” meta-cluster containing monocytes, macrophages, and dendritic cells. 
We next sought to determine whether differentiation of intratumoral myeloid cells 
was affected upon treatment. To address this, single-cell myeloid clusters were subject 
to a pseudo-temporal analysis using the Monocle2 package in R (Figure 2-7A).  
Monocle2 is an algorithm that aligns single cells based on gene expression along a 
trajectory that mirrors biological processes such as differentiation.  Cell populations from 
all four treatment conditions aligned as expected along the pseudotime trajectory. 
Immature myeloid-derived suppressor cells aligned earlier in pseudotime, while more 
terminally differentiated macrophage populations aligned later (Figure 2-7B).  
Examination of myeloid clusters within each treatment group did not reveal any 
differences in their distribution along the pseudotime trajectory (Figure 2-7C). Treatment 
with ICB, CD40 agonist, or both therefore does not appear to alter the differentiation 
state of myeloid cells within the tumor microenvironment. 
 
Intratumoral Myeloid Populations Upregulate CCL5 in Response to CD40 Activation 
We next queried transcriptional changes within each cluster as a function of 
treatment.  Differential gene expression analysis was used to compare gene expression 
in cell clusters isolated from CD40/ICB-treated vs. untreated tumors, beginning with the 
numerically predominant macrophages.  After filtering for genes that achieved an 
adjusted p-value < 0.05, we ranked genes based on absolute value of fold-change in 
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expression. The top 40 differentially expressed genes by adjusted p-value in 
macrophages from CD40/ICB-treated tumors compared to untreated tumors can be 
found in Table 2-1.  This list of genes was then intersected with genes known to be 
associated with T-cell trafficking. The most upregulated of these genes was Ccl5 (Figure 
2-2A).  Differential gene expression analysis of macrophages from CD40 agonist-treated 
vs. untreated tumors also yielded Ccl5. Notably, macrophages from tumors treated with 
ICB alone did not upregulate Ccl5.  The chemokine CCL5, also known as RANTES, is a 
T-cell chemoattractant that has been best described for its critical roles in immune 
control of viral infections141. The role of CCL5 in cancer remains incompletely examined, 
as it has been associated with both anti-tumor and pro-tumor functions including T-
regulatory cell attraction, progression and metastasis, tumor-associated macrophage 
function, and the indirect modulation of both CD8+ chemoattraction and repulsion142–147.   
To examine if other cell clusters upregulated Ccl5 in response to CD40 agonist 
treatment, a heatmap of Ccl5 expression was overlaid onto the UMAP visualization of 
our graph-based clustering (Figure 2-2B).  The macrophage, proliferating macrophage, 
monocyte, and cDC2 clusters all increased Ccl5 expression following CD40/ICB 
treatment – on the basis of both the proportion within each cluster expressing Ccl5 as 
well as the average expression of Ccl5 per cell (Figure 2-2C).  In contrast, Ccl5 
expression remained insignificant within the granulocyte, monocytic myeloid-derived 
suppressor cell (mMDSC), granulocytic myeloid-derived suppressor cell (gMDSC), and 
non-conventional monocyte populations, as none of these clusters expressed Ccl5 in 
more than 6% of their cells even following CD40 agonism.  The proportion of cells within 
the CD8+ T-cell and cDC1 clusters that expressed Ccl5 remained unchanged from 
baseline, though the average expression of Ccl5 per cell increased among CD8+ T-cells 
(Figure 2-2C).   
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To examine CCL5 induction at the protein level, 4662.MD10 tumor cells were 
subcutaneously implanted into C57BL/6J mice.  Mice were then treated with CD40/ICB 
and sacrificed on d12 post-treatment induction.  Tumors were harvested for flow 
cytometric analyses and cell subsets were gated according to the schema outlined in 
Figure 2-9A.  Consistent with our single-cell transcriptomic analysis, macrophages 
increased expression of CCL5 in response to treatment (Figure 2-3A-B).  Monocytes 
also increased expression of CCL5 in response to treatment (Figure 2-3A-B).  MDSCs 
did not express CCL5 in either the untreated or treated settings, nor did the CD45- 
compartment, comprised of tumor cells, stroma, and fibroblasts (Figure 2-3A-B).  In the 
T-cell compartment at baseline, relatively high CCL5 expression was observed in CD8+ 
T-cells and relatively low CCL5 expression was observed in CD4+ T-cells, both FoxP3+ 
and FoxP3- subpopulations (Figure 2-3C-D).  Consistent with single-cell transcriptomic 
analysis, the proportion of all T-cell subsets expressing CCL5 did not change as a result 
of treatment (Figure 2-3C-D).  The magnitude of CCL5 expression also remained 
unchanged in T-cells from CD40/ICB-treated tumors.   
To determine if CD40 agonism can directly induce CCL5 expression, F4/80+ 
splenic macrophages were isolated from C57BL/6J mice and cultured for 24 hours with 
cross-linked CD40 agonist mAb.  Macrophages cultured with CD40 agonist significantly 
upregulated CCL5 compared to unstimulated controls as quantified by flow cytometry 
(Figure 2-3E).  Having confirmed our findings at the protein level, we next set out to 
interrogate the functional relevance of CCL5 in the context of CD40/ICB immunotherapy.   
 
CCL5 Mediates CD40/ICB Treatment Efficacy  
To determine whether CCL5 is required for response to CD40 agonism, we 
implanted syngeneic CCL5 genetic knockout mice (B6.129P2-Ccl5tm1Hso/J) with 
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4662.MD10 and compared tumor growth kinetics and survival to C57BL/6J wild-type 
controls. A subset then received CD40/ICB while another subset was left untreated, as 
described in Figure 2-10A.  Additionally, we observed that the 4662.MD10 tumor cell line 
expresses MHC class I but not MHC class II following IFN-gamma treatment in vitro 
(Figure 2-9B). Tumors in WT mice responded as expected to treatment with CD40/ICB, 
both in terms of tumor growth retardation (Figure 2-4A) and rate of tumor regressions 
(Figure 2-4B).  In CCL5 KO mice, however, while the treatment effect of CD40/ICB-
treated mice remained directionally true, the effect was no longer observed at the 
statistically significant level relative to untreated CCL5 KO controls (Figure 2-4A-B).  
Over the course of the entire experiment (75 days), CD40/ICB-treated CCL5 KO mice 
bearing tumors exhibited statistically worse long-term survival than tumor-bearing wild-
type controls (Figure 2-4C), consistent with a potential role of CCL5 in mediating 
response to CD40/ICB immunotherapy.   
T-cells from CCL5 KO mouse are known to have baseline defects with potential 
but unknown compensation during development182. To rule out this potential confounder, 
we used a pharmacological inhibitor of CCL5 given just prior to therapy in wild type mice 
to extend our observations. C57BL/6J mice were subcutaneously injected with 
4662.MD10 and were treated with CD40/ICB, anti-CCL5, both, or neither, according to 
the schema in Figure 2-10B. CCL5 blockade alone did not affect tumor growth, nor 
impact the rate of tumor progression, compared to control antibody (Figure 2-4D, E). 
Although CD40/ICB showed major tumor growth delay and high rate of tumor 
regressions, these effects were abrogated with the addition of anti-CCL5 to CD40/ICB 
treatment. Additionally, tumor bearing mice treated with anti-CCL5 and CD40/ICB had 
significantly worse long-term survival compared to those treated with CD40/ICB alone 
(Figure 2-4F).   
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We next sought to determine which immune cell types mediated this treatment 
dependency on CCL5.  We used flow cytometry to compare the T-cell content of 
untreated tumors in wildtype and CCL5 KO mice 16 days after subcutaneous 
implantation with 4662.MD10. CCL5 KO mice had statistically significantly lower 
proportions of FoxP3+ CD4+ T-cells among all CD45+ cells in the tumor compared to 
wildtype, although no differences were otherwise found in total T-cell, FoxP3- CD4+ T-
cell, or CD8+ T-cell quantity (Figure 2-5A).  We next examined the effect of CCL5 
blockade on the tumor microenvironment of tumor-bearing wildtype mice, with or without 
CD40/ICB.  In contrast to CCL5 KO mice, wildtype tumor-bearing mice treated with anti-
CCL5 did not have altered T-cell content compared to untreated mice at day 12 post-
treatment (Figure 2-5B). Treatment with CD40/ICB, as expected, increased the 
percentage of total T-cells, CD4+ T-cells, and CD8+ T-cells133. The addition of anti-CCL5 
to CD40/ICB at the same time point, however, decreased total T-cell infiltration and 
abrogated the FoxP3- CD4+ T-cell influx in response to therapy.  Notably, CCL5 
blockade did not affect the proportion of FoxP3+ CD4+ T-cells or CD8+ T-cells. These T-
cell infiltration dynamics were also observed at the level of cells per unit volume of 
tumor, indicating that CCL5 modulates absolute infiltration and is not simply repolarizing 
the immune infiltrate (Figure 2-11).  FoxP3- CD4+ and CD8+ T-cells in the tumor 
microenvironment were further examined for expression of T-cell activation markers. 
None of these markers changed in CD8+ T-cells in any treatment or control condition 
(Figure 2-5C). In contrast, a number of changes were observed in CD4+ T-cells in both 
the untreated and CD40/ICB-treated settings.  Anti-CCL5 treatment alone increased the 
percentage of CD4+ T-cells expressing CD39, LAG-3, and PD-1, and CD40/ICB 
decreased the percentage of cells expressing LAG-3 and markedly increased PD-1+ 
cells compared to untreated controls (Figure 2-5D). The addition of anti-CCL5 to 
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CD40/ICB also increased the percentage of CD4+ T-cells expressing CD39, restored the 
percentage of cells expressing LAG-3, and did not affect PD-1, compared to CD40/ICB 
treatment without anti-CCL5.  
The best characterized receptor for CCL5 is CCR5148.  CCR5 expression on 
intratumoral T-cells was confirmed by flow cytometry but did not change as a function of 
either CD40/ICB treatment or CCL5 blockade (Figure 2-5E).  To determine whether 
CD4+ T-cell trafficking to the tumor after CD40/ICB was mediated by CCR5, an equal 
mixture of CCR5 KO and wild-type CD4+ T-cells was adoptively transferred into tumor-
bearing mice thirteen days post-tumor implantation.  Mice were then treated with 
CD40/ICB according to the schema in Figure 2-10B and sacrificed seven days later to 
compare the ability of CCR5 KO T-cells (as distinguished by an allelic marker) to traffic 
to the tumor relative to WT control T-cells.  Tumors of untreated mice contained equal 
proportions of CCR5 KO and wild-type CD4+ T-cells but tumors from CD40/ICB-treated 
mice contained more than twice as many wild-type CD4+ T-cells on average than CCR5 
KO cells (Figure 2-5F).  Thus, CCR5 is at least partially responsible for CD4+ T-cell 






CD4+ T-cells are critical mediators of tumor immunity but mechanisms of 
intratumoral CD4+ T-cell chemotaxis remain incompletely understood.  Our group has 
previously demonstrated that CD40 agonism drives CD4+ T-cell tumor influx and 
synergizes with ICB in a CD4+ and CD8+ T-cell-dependent manner.  Here, we report 
that the chemokine CCL5 is broadly induced in myeloid populations after treatment with 
agonist CD40 mAb. Using a suite of genetic and pharmacologic experiments in vivo, we 
show that CCL5 mediates CD4+ T-cell tumor influx via CCR5 following CD40 therapy. 
The effect of CCL5 is selective for CD4+ T-cells, not CD8+ T-cells. Therapeutic benefit is 
significantly diminished in the absence of CCL5.  Overall, our results demonstrate a 
previously unappreciated role for CCL5 that underlies the therapeutic adaptive immune 
response to CD40 agonist.   
Given the diverse nature of CD40 expression, it has long been appreciated that 
the activity of CD40 agonist is likely pleiotropic.  CD40 agonism has been shown to have 
antitumor effects on a number of CD40-expressing myeloid cell types. Macrophages 
have been shown to remodel tumor stroma after CD40 agonist178.  Monocytes have 
been shown to degrade fibrosis and enhance the effects of chemotherapy upon CD40 
activation183.  We have also observed that the anti-tumor efficacy of CD40 agonist 
requires cDC1s, the subset of dendritic cells uniquely capable of antigen cross-
presentation74,132,133.  However, due to past technological limitations, it has been difficult 
to query all CD40-expressing cell types simultaneously following treatment.  The recent 
emergence of single-cell RNA sequencing allows us to examine these pleiotropic effects 
in a highly dimensional and unbiased manner for the first time.  Our single-cell 
transcriptomic analysis reveals an upregulation of the chemokine CCL5 across a broad 
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range of myeloid cells following CD40 agonism.  This is shown to critically and 
selectively mediate CD4+ T-cell chemotaxis and immune control of tumor outgrowth 
following therapy.  Thus, we demonstrate that the anti-tumor effects of CD40 agonism 
are largely dependent on the upregulation of a single chemokine. 
Our findings raise several additional preclinical questions of interest for future 
studies.  This study was performed in a subcutaneously transplanted model of 
pancreatic cancer, which facilitated the single cell analysis.  T-cell trafficking to the 
pancreas in orthotopic or autochthonous models in response to CD40/ICB therapy may 
operate under different biology.  Whether our findings extend to other priming-deficient 
cancers beyond PDAC is also of significant interest.  In addition, while we have no 
evidence to support a role for CCL5 beyond attracting CD4+ T-cells to the tumor, we 
cannot eliminate that possibility.  Finally, while our results demonstrate the dominance of 
CCR5 in this system, chemokine-chemokine receptor interactions are notoriously 
complex and supplemental or compensatory roles for other CCL5 receptors may exist.   
Past manipulations of the CCL5-CCR5 signaling axis in cancer patients have 
been dominated by the use of CCR5 antagonists to mitigate T-regulatory cell and tumor 
associated macrophage infiltration143,149,150.  CCR5 inhibition has also been used in 
attempts to sensitize tumors to chemotherapy and prevent metastasis, and shows 
promise as a means of preventing visceral graft versus host disease in cancer patients 
after allogenic bone marrow transplant151–154.  Our finding that T-regulatory cell content is 
reduced in tumors implanted into CCL5 knockout mice corroborates these findings and 
supports the use of these inhibitors at baseline prior to immunotherapy.  However, our 
findings suggest further that the use of CCR5 antagonists may be harmful with continued 
use once an immune response is initiated.  This may have immediate clinical relevance 
for at least two ongoing clinical trials (NCT03631407, NCT03274804) combining the 
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CCR5 small molecule inhibitors maraviroc and vicriviroc with the PD-1 inhibitor 
pembrolizumab.  Moving forward, our data should inform the optimal combinations in 
which CCR5 inhibitors are administered.   
CD40 agonist immunotherapies are currently being tested in clinic 
(NCT03214250, NCT02588443)135,137,138.  Early results are promising, especially in 
combination with PD-1 inhibitors.  A particularly promising trial was recently performed in 
which pancreatic adenocarcinoma patients received a CD40 agonist mAb (APX005M) in 
addition to standard-of-care gemcitabine/nab-paclitaxel chemotherapy138.  The overall 
response rate was 54.2%, compared to historical controls of 18% with standard-of-care 
chemotherapy alone.  Moving forward, CCL5 can be evaluated as a potential biomarker 
of response to CD40 agonism in these clinical studies.  Finally, our findings also provide 
rationale for enhancing CD40 agonist or other cancer immunotherapies through ectopic 
delivery of CCL5 using CCL5-expressing oncolytic viruses or intratumoral injection of 




Materials and Methods 
 
Animal Studies 
Mice were housed under specific pathogen-free conditions in a barrier facility. 
C57BL/6J mice were purchased from Jackson Laboratories; B6.129P2-Ccl5tm1Hso/J 
(CCL5 KO) mice were purchased from Jackson Laboratories or bred in-house. Tumor 
cell lines were derived from spontaneous tumors in the KPC (LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx-1-Cre) mouse model of PDAC124 as previously described184. 4662 is 
a polyclonal KPC cell line and 4662.MD10 is a clonal KPC cell line derived from 4662.  
Cell culture was performed in DMEM supplemented with 10% FBS, L-glutamine, and 
gentamycin.   
Transplanted tumors were generated by injecting 3x105 cells in serum-free 
DMEM subcutaneously into the right flank.  Tumors were then allowed to grow for 14 
days (average size, 30-60mm3).  Mice were assigned to groups such that average tumor 
volume at baseline did not vary by treatment condition.  Tumors were measured every 
three days by caliper.  Tumor volumes were calculated using the formula (L x W2)/2, 
where “L” is the longer diameter and “W” is the diameter perpendicular to “L.”  For 
survival studies, mice were deemed to have reached endpoint when their tumor 
exceeded 500mm3.  Mice that died suddenly or developed large tumor ulcerations were 
censored from survival studies on the day of death or euthanasia.   
 
In vivo Antibody Studies 
Mice were treated intraperitoneally with immune checkpoint blockade (αPD-1: 
RMP1-14; BioXcell; 200 µg/dose on days 0, 3, 6, 9, and 12 and αCTLA4: 9H10; 
BioXcell; 200µg/dose on days 0, 3, 6) and CD40 agonist (FGK45; BioXcell; endotoxin-
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free; 100 µg/dose) on day 3.  For CCL5 blockade studies, mice were treated 
intraperitoneally with αCCL5 blocking antibody (PeproTech; 32μg/dose on days -1, 2, 5, 
8, & 11) or polyclonal rabbit isotype control (PeproTech; 32μg/dose on days -1, 2, 5, 8, & 
11).   
 
Tissue Processing and Flow Cytometry 
Mice were sacrificed on day 12 post-treatment.  The entire tumor was dissected, 
washed in DMEM-F12 + 10% FBS, minced into small fragments and digested in DMEM-
F12 with 1 mg/ml collagenase and protease inhibitor (Sigma-Aldrich C6079) for 30 min 
at 37C.  Cells were then filtered through a 70 μm cell strainer then 40 μm strainer.   
Tissue-derived cells were washed with PBS before viability stain with LIVE/DEAD 
Fixable Aqua (Invitrogen L34957) for 20 min at room temperature. Samples were then 
washed with FACS Buffer (PBS w/ 0.2% BSA + 2 mM EDTA) before being stained for 
surface markers for 30 min at 4C. Samples were then fixed and permeabilized using the 
eBioscience Fixation/Permeabilization kit (eBioscience 88-8824-00) and stained 
intracellularly overnight at 4C.  Flow cytometry antibodies can be found in Table 2-2.  
Samples were collected on an LSR Fortessa Flow Cytometer (BD Biosciences).  Data 
were analyzed using FlowJo v10 (Treestar).   
 
In Vitro Stimulation Assay 
Spleens from five female C57BL/6J mice were isolated and macrophages were 
enriched by magnet assisted cell sorting (MACS) column using the F4/80 positive 
selection kit (Miltenyi 130-110-443).  Macrophages were cultured in a 96-well plate 
overnight in an incubator at 37C in DMEM w/ 10% FBS, L-glutamine, and gentamycin 
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and stimulated with cross-linked CD40 agonist (FGK45; BioXcell; endotoxin-free).   Cells 
were stained for CCL5 by flow cytometry the following day as described above.   
 
Single-cell RNA Sequencing Library Generation 
5,000 live CD45+ cells were isolated from each tumor by fluorescence activated 
cell sorting (FACS) using the 100 µm nozzle on a BD Biosciences Aria II. Sorted cells 
were then barcoded and used to generate single-cell RNA libraries with the droplet-
based 10X Genomics Chromium platform according to manufacturer’s protocol. Library 
quality was verified with an Agilent BioAnalyzer and LifeTech QuBit fluorimeter. Libraries 
were then sequenced as 150bp paired-end reads on an Illumina HiSeq4000 to a depth 
of approximately 312 million read pairs. 
 
Library Alignment, Barcode Assignment, and UMI Counting 
10X Genomics’ Cell Ranger Single-Cell Software Suite v. 3.1.0 was used to 
perform sample demultiplexing, barcode processing, and single-cell 3’ counting from the 
generated fastq files. The “count” function was used to align samples to the mm10 Mus 
musculus genome, filter cells, and quantify reads. The resulting analysis files were 
aggregated per treatment group using the “aggr” function which performs between-
sample normalization and sample merging. These combined datasets were used as 
input into Seurat v3.0 on R v. 3.6.1185,186. 
 
Preprocessing 
Cells that contained reads for over 2,500 or less than 200 genes were excluded 
as doublets or empty wells, respectively. Cells that contain reads for which >5% align to 
mitochondrial genes were excluded as dead cells. Data was normalized with a scale 
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factor of 104. Highly variable genes between cells were identified using variance 
stabilizing transformation (“vst”) which directly models mean-variance relationships 
within single-cell datasets. The number of cells in each treatment group was then 
reduced to 2,072 cells. Batch correction within treatment groups was performed using 
the “FindIntegrationAnchors” and “IntegrateData” functions, generating a “batch-
corrected” expression matrix. Cells across all treatment groups were then integrated into 
a single dataset using the same functions (i.e., “FindIntegrationAnchors” and 
“IntegrateData”). 
 
Linear Dimensional Reduction and Clustering 
The fully merged dataset was linearly transformed using the “ScaleData” function 
such that the mean expression of a given gene across all cells was 0 and the variance of 
that gene across all cells was 1. Linear dimensional reduction was then performed using 
principal component analysis. Based on the distribution of p-values per principal 
component, the first 20 principal components were used to cluster cells using the 
“FindNeighbors” and “FindClusters” functions which implement SNN (shared nearest 
neighbor) modularity optimization-based clustering. This was performed using a chosen 
resolution of 0.5, yielding 16 total clusters. Non-linear dimensional reduction was then 
performed using UMAP (Uniform Manifold Approximation and Projection) to visualize 
clusters in two-dimensional space. 
 
Cluster Identification 
To identify cell type within a given cluster, the “FindConservedMarkers” function 
was used to identify genes for which expression was conserved across treatment 
groups. This function performs differential gene expression testing for each treatment 
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group and combines the p-values using meta-analysis methods from the MetaDE R 
package. Cell type identities were then assigned to clusters based on identification of 
canonical cell markers and characterization of top conserved genes using the 
MyGeneSet tool from the Immunological Genome (ImmGen) Project. Clusters that 
comprised contaminating non-immune populations (i.e., tumor cells and fibroblasts) were 
removed. Scaled expression of conserved marker genes were used for heatmap 
representation. 
 
Differential gene expression analysis 
A Wilcoxon Rank Sum test was used to identify differentially expressed genes 
between two treatment groups within a given cluster. The fold-change in expression and 
adjusted p-value for each gene were used for volcano plot representation using the 
ggplot2 R package. After filtering for genes with an adjusted p-value < 0.05, genes were 
then ranked based on highest-to-lowest absolute value of fold-change. 
 
Pseudotime Analysis 
Myeloid clusters identified using Seurat (as described above) were used as input 
to the Monocle v. 2.4.0 R package187. Genes expressed in 10 or more cells were ranked 
based on differential analysis between clusters. Genes with a q-value < 0.01 were used 
for downstream pseudo-temporal analysis. Dimensionality reduction was done using the 
DDRTree method. Cells were ordered along pseudotime trajectory with the orderCells 







Comparison of two groups was performed using two-tailed Student’s t test unless 
otherwise indicated.  Tumor growth curves were analyzed by two-way ANOVA, with 
Tukey multiple comparisons of means as a post hoc test to assess differences between 
any two groups.  Survival curves were compared using log rank (Mantel-Cox) test.  
Statistical analyses were performed in Prism 7 (GraphPad) or Excel (Microsoft).  P < 
0.05 was considered statistically significant and * denotes p < 0.05, ** p <0.01, *** p < 
0.001, and **** p <0.0001.  
 
Study Approval 
All mouse experiments were performed at the Perelman School of Medicine of 
the University of Pennsylvania in accordance with University IACUC and ULAR 









Figure 2-1 Single-cell RNA sequencing identifies intratumoral immune populations. 
(A) Treatment of mice subcutaneously implanted with clonal KPC cell line 4662.MD10 
with combination CD40 agonist and anti-CTLA-4 + anti-PD-1 (ICB). CD45+ cells 
were sorted for single-cell transcriptomic analysis using the 10X Genomics platform 
12 days after beginning therapy. 
(B) Tumor growth kinetics of subcutaneously implanted mice treated as shown in Fig. A.  
(C) UMAP non-dimensional linear reduction and clustering of immune cell populations 
from the tumor microenvironment merged across all treatment conditions. 
(D) Scaled expression of cluster-specific genes visualized by heatmap. The mean 
expression of each gene across all clusters was scaled to 0 with a variance of 1. 
(A, C, and D): n=4 mice per treatment group. (B): n=10 mice per group. Error bars 
indicate mean +/- SEM. *p<0.05 (Student’s two-tailed t-test). Data shown in Fig. B are 
representative of two independent experiments with five to ten mice per group.  These 








Figure 2-2 Anti-tumor myeloid populations upregulate Ccl5 transcripts after CD40 
activation. 
Differential gene expression analysis was performed on immune cell clusters from the 
tumor microenvironment as resolved by UMAP non-linear dimensional reduction shown 
in Figure 2-1. 
(A) Volcano plot of differentially expressed genes in macrophages as a function of 
treatment. 
(B) Expression of Ccl5 overlaid onto UMAP clusters.  Color intensity scale represents 
average number of Ccl5 transcripts per Ccl5+ cell.   
(C) Proportion of cells positive for reads of Ccl5 gene transcript in immune clusters from 
untreated vs combination treated (CD40/ICB) tumors. Size of circle indicates 
proportion of cells within a cluster positive for Ccl5 transcript.  Color intensity scale 
represents average number of Ccl5 transcripts per Ccl5+ cell.   








Figure 2-3 CCL5 is upregulated by anti-tumor myeloid populations following CD40/ICB 
therapy. 
Female C57BL/6J mice were subcutaneously transplanted with 3x105 4662.MD10 cells 
and treated with CD40/ICB as shown in Figure 2-1A. Flow cytometric analysis of tumors 
was then performed on day 12 following initiation of therapy. Gating scheme for flow 
cytometric analysis is shown in Figure 2-9A.   
 (A and B) Expression of CCL5 in intratumoral macrophages, monocytes, MDSCs, and 
the CD45(-) compartment from untreated vs CD40/ICB treated mice. 
(C and D) Expression of CCL5 in intratumoral CD8+ T-cells, CD4+ T-cells, and FoxP3+ 
T-regulatory cells from untreated vs CD40/ICB-treated mice.   
 (E) Proportion of CCL5-expressing macrophages.  Splenic macrophages were isolated 
and cultured for 24 hours either unstimulated or stimulated with cross-linked αCD40 
mAb.   
(A-D): n=3 mice per group. *p≤0.05, **p≤0.01 (one-tailed Student’s t-test). Data shown 
are representative of three independent experiments with three to five mice per group. 
(E): n=5 mice per group.  *p≤0.05 (paired, one-tailed Student’s t-test). Data shown are 








Figure 2-4 CCL5 is required for treatment efficacy. 
(A) 3x105 4662.MD10 cells were subcutaneously implanted into C57BL/6J or B6.129P2-
Ccl5tm1Hso/J CCL5 knockout mice. Mice were treated with CD40/ICB as shown in 
Figure 2-10A.  Tumor growth kinetics shown over the course of treatment. 
(B) Change in tumor volume of mice from Fig. (A) on day 24 (or most recent available) 
compared to day 0. 
(C) Survival of mice of mice from Fig. (A) from each treatment group.  
(D) 3x105 4662.MD10 cells were subcutaneously implanted into C57BL/6J mice that 
were then treated with CD40/ICB and/or CCL5-blocking antibody as shown in Figure 2-
10B.  Tumor growth kinetics shown over the course of treatment.   
(E) Change in tumor volume of mice from (D) on day 16 (or most recent available) 
compared to day 0. 
(F) Survival of mice from (D) from each treatment group.  
(A-B): n=10 mice per group. (C): combined results of two identical experiments with 
n=10 mice per group. (D-F): n=10 mice per group. ****p≤0.0001, ***p≤0.001, **p≤0.01, 
*p≤0.05 (one-way ANOVA with Tukey’s HSD post-test in A and D; Log-rank test in C and 









Figure 2-5 CCL5 is required for CD4+ T-cell infiltration following CD40/ICB. 
(A) Enumeration of T-cell populations by flow cytometry in tumors of untreated CCL5 KO 
and WT control mice on day 16 post-implantation.  
(B) Enumeration of T-cell populations in tumors of mice treated with combination 
CD40/ICB +/- αCCL5 day 12 post-implantation, as outlined in Figure 2-10B.  
(C) Expression of T-cell activation markers on CD4+ T-cells from (B).   
(D) Expression of T-cell activation markers on CD8+ T-cells from (B).   
(E) Expression of CCR5 on CD8+ T-cells, CD4+ T-cells, and FoxP3+ T-regulatory cells 
from (B).   
 (F) Enumeration of adoptively transferred WT or CCR5 KO CD4+ T-cells identified by 
flow cytometry in tumors of mice treated with combination CD40/ICB relative to 
untreated mice.  Data in (F) were generated by Kate Byrne.   
 
(A): n=6 C57BL/6J and n=8 CCL5 KO mice. 
(B-E): n=3-5 C57BL/6J mice each group. ****p≤0.0001, ***p≤0.001, **p≤0.01, *p≤0.05 
(two-tailed Student’s t-test in A-E; two-tailed paired Student’s t-test in F).   Data shown 








Figure 2-6 Single cell analysis pipeline and details. 
(A) Cell and transcriptomic metrics from each single-cell library. Metrics were generated 
using the 10X Genomics CellRanger 3.0 software. 
(B) Single-cell transcriptomic analysis pipeline following library sequencing. Software 
packages are color-coded. 









Figure 2-7 Myeloid cell differentiation is unaffected by treatment with CD40 agonist and 
immune checkpoint blockade. 
(A) Pseudotime trajectory of myeloid cell clusters across all treatment groups as 
calculated using Monocle2. 
(B) Plots of each myeloid cell cluster along pseudotime trajectory. 
(C) Pseudotime trajectory of myeloid cell clusters split by treatment group. 
(A): n=6,510 cells from myeloid cell clusters across all treatment groups as determined 
in Seurat were used as input for Monocle pseudotime analysis. (B): n=1,764 
macrophages, n=1,301 mMDSCs, n=1218 granulocytes, n=802 gMDSCs, n=710 non-
conventional monocytes, n=252 monocytes, n=241 proliferating macrophages, and 
n=222 cDC2s shown. (C): n=1,448 untreated, n=1,635 ICB, n=1,284 CD40 agonist, 
n=2,143 CD40/ICB cells shown. These data were generated and analyzed in 








Figure 2-8 Proportion of each immune cell cluster split by treatment group. 









Figure 2-9 Supplemental flow cytometry. 
(A) Gating scheme for flow cytometric identification of immune populations in a 
representative subcutaneously implanted KPC tumor. 
(B) Flow cytometry comparison of 4662.MD10 and B16-F10 MHCII expression.  These 








Figure 2-10 Treatment schema.  
(A) Treatment schema of C57BL/6J and CCL5 KO mice subcutaneously implanted with 
clonal KPC cell line 4662.MD10 with combination CD40/ICB. 
(B) Treatment schema of C57BL/6J mice subcutaneously implanted with clonal KPC cell 











Figure 2-11  T-cell subsets per gram of tumor.  
Enumeration of T-cell populations per gram of tumor in mice treated with combination 




  p_val avg_logFC p_val_adj 
Ccl5 9.48E-15 1.64375 2.95E-10 
Slpi 4.58E-12 1.32228 1.42E-07 
Cxcl9 6.57E-13 1.29667 2.04E-08 
C3 6.84E-22 1.27328 2.12E-17 
Dusp1 9.80E-13 1.26357 3.04E-08 
AA467197 3.52E-11 1.1813 1.09E-06 
Ass1 7.62E-18 1.1622 2.37E-13 
Ly6i 6.51E-24 1.06324 2.02E-19 
Clec4d 8.96E-18 1.05614 2.78E-13 
Neat1 1.30E-13 1.02051 4.05E-09 
AW112010 7.45E-14 0.98972 2.31E-09 
Fth1 3.87E-25 0.96366 1.20E-20 
H2-Q7 8.31E-15 0.94834 2.58E-10 
Ly6a 1.77E-19 0.91886 5.49E-15 
Acod1 4.99E-14 0.84767 1.55E-09 
Txn1 6.17E-15 0.80481 1.92E-10 
Fosb 2.33E-13 0.72134 7.23E-09 
Bst1 1.25E-17 0.70764 3.90E-13 
B2m 2.21E-13 0.66535 6.87E-09 
C1qc 8.51E-12 -0.42674 2.64E-07 
mt-Nd1 2.22E-11 -0.42989 6.89E-07 
C1qa 7.49E-13 -0.43631 2.33E-08 
mt-Co2 1.47E-13 -0.44139 4.56E-09 
mt-Cytb 1.89E-13 -0.44456 5.86E-09 
mt-Nd4 1.88E-11 -0.44992 5.84E-07 
mt-Co3 1.27E-15 -0.47723 3.94E-11 
Tpm3 1.19E-13 -0.50229 3.69E-09 
Ms4a7 7.37E-12 -0.64787 2.29E-07 
mt-Nd3 1.73E-13 -0.65141 5.36E-09 
mt-Atp6 1.02E-22 -0.66727 3.17E-18 
Dab2 4.80E-15 -0.69147 1.49E-10 
Fcrls 5.70E-12 -0.69249 1.77E-07 
Tmem176a 1.45E-13 -0.70649 4.49E-09 
Tmem176b 1.99E-12 -0.72074 6.18E-08 
Mgl2 1.84E-14 -0.73344 5.71E-10 
Lars2 7.17E-20 -0.78017 2.23E-15 
Cd81 9.48E-17 -0.78229 2.94E-12 
Apoe 5.75E-22 -0.86455 1.79E-17 
Selenop 1.24E-17 -0.91699 3.86E-13 





The 40 most significantly changed genes in macrophages treated with CD40/ICB relative 
to untreated controls, arranged by average log fold-change.  Corresponds to Figure 2-2.    
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Target Clone Fluorophore Source 
F4/80 BM8 FITC BioLegend 
CD11b M1/70 PerCP-Cy5.5 BD 
CCL5 2E9/CCL5 PE BioLegend 
CD64 X54-5/7.1 PE-CF594 BioLegend 
FoxP3 FJK-16s PE-Cy5 Invitrogen 
CD8a 53-6.7 PE-Cy7 BD 
CD11c HL3 APC BD 
CD45 30-F11 AF700 BioLegend 
NK1.1 PK136 APC-Cy7 BioLegend 
CD103 2E7 BV421 BioLegend 
Viability n/a LD Aqua Invitrogen 
Ly6C HK1.4 BV605 BioLegend 
CD3 17A2 BV650 BioLegend 
CD19 6D5 BV711 BioLegend 
B220 RA3-6B2 BV711 BioLegend 
I-A/I-E M5/114.15.2 BV785 BioLegend 
CD4 GK1.5 BUV395 BD 
Ly6G 1A8 BUV805 BD 
Tim3 RMT3-23 FITC Invitrogen 
LAG-3 C9B7W PerCP-Cy5.5 BioLegend 
CTLA-4 UC10-4B9 PE-CF594 BioLegend 
CD62L MEL-14 PE-Cy5 BioLegend 
CD39 Duha59 AF647 BioLegend 
FoxP3 MF-14 BV421 BioLegend 
PD-1 29F.1A12 BV605 BioLegend 
NK1.1 PK136 BV711 BioLegend 
CD44 IM7 BV785 BioLegend 







Target, clone, fluorophore, and source for flow cytometry antibodies used for 







CHAPTER 3 – CD40 AGONISM REVERSES DEFICIENT PRIMING 
IN PANCREATIC CANCER 
 
Parts of this chapter were previously published in: 
 
Lin JH; Huffman AP, et al.  Type 1 conventional dendritic cells are systemically 
dysregulated early in pancreatic carcinogenesis. Journal of Experimental Medicine, 




The second major project of my thesis interrogated the dysregulation of dendritic 
cells in pancreatic cancer and the reversal of that dysfunction through systemic CD40 
agonism.  Recently published in the Journal of Experimental medicine, this project was 
primarily driven by Jeffrey Lin during the early stages of my time in the lab.  My 
contribution to this project was in the generation of data early in the manuscript, and 
what appears below is the subset of that manuscript to which I contributed.  Each figure 
contained in this chapter, therefore, was generated by both Jeffrey Lin and I.   
In some cancers, anti-cancer T-cells exist but are evaded or excluded by 
tumors188. In “cold” ICB-resistant tumors, however, anti-cancer T-cells are absent from 
the earliest stages of disease and exhibit no evidence of T-cell-mediated 
immunoediting189,190.  The immune dysregulation in these tumors, therefore, is more 
consistent with deficient T-cell priming – resulting in a baseline paucity of anti-cancer T-
cells – rather than evasion of pre-existing T-cell immunity74.   
Type 1 conventional dendritic cells (cDC1s) are the primary antigen presenting 
cell (APC) drivers of anti-tumor adaptive immunity191.  They mediate tumor antigen 
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trafficking to draining lymph nodes and drive CD8+ T-cell antitumor activity through 
cross-presentation192–194.  cDC1s also recruit CD8+ T-cells to the tumor itself179.  They 
have also been shown to be critical dependencies of T-cell-mediated tumor rejection in 
both spontaneous and ICB-driven settings across multiple murine cancer 
models119,179,191,193,195–197.  It was recently shown in murine PDAC that DC paucity gives 
rise to dysfunctional immune surveillance against an engineered neoantigen198. Finally, 
melanoma have been shown to directly mediate cDC1 suppression and exclusion 
through cancer cell-intrinsic signaling mechanisms like β-catenin119,179,196. Clearly, cDC1s 
are critical mediators of anti-cancer adaptive immunity.  Defining the extent of cDC1 
dysregulation and developing strategies to reverse that phenomenon are critical areas of 
ongoing study in the field of cancer immunology.   
To that end, we here examine the temporal dynamics of cDC1 dysregulation 
during carcinogenesis. We use the KPC mouse model of PDAC, driven by Pdx1-Cre 
KrasLSL-G12D/+ Trp53LSL-R172H/+, to study the immune dynamics of cDC1s and T-
cell priming during the development of carcinoma from inception to invasion124,189.  KPC 
mice develop preinvasive pancreatic intraepithelial neoplasias (PanINs) that progress to 
metastatic carcinomas. PanIN formation results in an influx of tumor-associated 
macrophages, myeloid-derived suppressor cells (MDSCs), and FoxP3+ T-regulatory 
cells.  Upon progression to malignancy these immunosuppressive populations expand 
through the recruitment of myeloid cells by tumor-derived GM-CSF and CXCR2199,200.  
KPC tumors have minimal baseline T-cells, a phenomenon that is consistent with 
dysregulated T-cell priming.  Using the KPC mouse model, we demonstrate defects in 
cDC1 abundance and maturation beginning in preinvasive neoplasia and progressing to 
invasive carcinoma. We reveal that these defects are present at the systemic level and 
impair CD8+ T-cell priming from the earliest stages of disease. Furthermore, we 
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demonstrate that CD40 agonist therapy reverses this maturation defect and restores T-







cDC1 Abundance Declines Progressively and Systemically During Pancreatic 
Carcinogenesis 
Eight-week-old KPC mice were confirmed to have stage 1A PanINs in the 
pancreas (Fig. 3-1A; hereafter “PanIN-bearing”). KPC mice with ultrasound-confirmed 
tumors served as “tumor-bearing” mice.  Finally, Pdx1-Cre mice wild-type for Kras and 
Trp53 served as “healthy” mice.  cDCs were defined as live CD45+ CD64- Lin- MHC II+ 
CD11c+ cells, and cDC1s and cDC2s were further subdivided by XCR1 and SIRPα 
expression, respectively (Fig. 3-1B)201. cDC1 abundance declined in PanIN-bearing 
pancreas and KPC tumor both as a proportion of live cells and as a proportion of CD45+ 
immune cells (Fig. 3-1C).  cDC1 abundance similarly declined in the tumor-draining peri-
pancreatic lymph nodes (ppLNs) (Fig. 3-1D).  
To evaluate cDC1 abundance systemically we also quantified them in the breast 
pad-draining inguinal lymph nodes (iLNs) and spleen (Fig. 3-1, E and F). cDC1s in these 
distant tissues also declined both as a proportion of total live and CD45+ cells in PanIN- 
and tumor-bearing mice. When calculated based on tissue weight, however, cDC1 
numbers were not altered (Fig. 3-9).  In sum total, our evaluation of cDC1 abundance in 
the KPC model unveiled a progressive and systemic decline in cDC1s beginning as 
early as the PanIN stage.  
 
cDC1 Abundance in Patients with Pancreatic Cancer 
To determine whether this decline in cDC1 abundance was also characteristic of 
human disease, we analyzed cDC1s in the peripheral blood of newly diagnosed, 
untreated PDAC patients (n=17) using mass cytometry.  Indeed, CD141+ cDC1s were 
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markedly decreased in PDAC patients compared to healthy volunteers (n=10) (0.031% 
vs. 0.068%; p=0.02) (Fig. 3-1G).  
 
cDC1 Maturation is Progressively and Systemically Impaired During Pancreatic 
Carcinogenesis 
We next set out to determine if, in addition to their quantitative deficiency, cDC1s 
were qualitatively diminished by carcinogenesis.  Immature DCs become mature upon 
encounter of an activating “danger” signal (ex TLR stimulation) during homeostatic tissue 
surveillance and antigen uptake202.  Upon this stimulation DCs then mature and traffic to 
the tissue-draining lymph node by CCR7 upregulation, where they present antigen and 
prime T-cells192.  cDC1s in particular upregulate antigen processing and cross-
presentation machinery, increase expression of the cell surface molecules CD40, CD80, 
CD86, MHC II, and PD-L1, and produce T cell-polarizing cytokines such as IL-12 to 
induce Th1 CD4+ T cell differentiation and CD8+ T cell activation203. 
Therefore, to evaluate this typical maturation process in the context of PDAC 
oncogenesis, we utilized flow cytometry to characterize cDC1 expression of CD40, 
CD80, CD86, MHC II, and PD-L1.  cDC1 CD40 and CD86 expression increased in KPC 
tumors relative to healthy and PanIN-bearing pancreas, but the expression of CD80, 
MHC II, and PD-L1 remained unchanged (Fig. 3-2A). This incomplete upregulation of 
maturation markers is consistent with a phenomenon previously described as DC semi-
maturation, which is associated with T-cell priming deficiencies in cancer patients204,205.  
This cDC1 semi-maturation occurred in the draining ppLN as early as the PanIN-bearing 
stage (Fig. 3-2B).  Also in the ppLN, CD40, CD86, and PD-L1 expression increased, but 
CD80 and MHC II expression declined in PanIN mice.  These expression patterns were 
amplified in tumor-bearing mice.  This cDC1 maturation marker expression pattern was 
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also seen systemically, resulting in decreased expression of CD80, CD86, MHC II, and 
PD-L1 in the iLNs and spleen of PanIN- and tumor-bearing mice (Fig. 3-2, C and D). 
Therefore, cDC1s are qualitatively (as shown by maturation marker expression) as well 
as quantitatively (as shown by abundance) deficient in a systemic and progressive 
manner, beginning in preinvasive carcinogenesis.   
We next performed bulk RNA sequencing on ppLN cDC1s from healthy, PanIN-
bearing, and tumor-bearing mice. Principal component and differential gene expression 
analyses were suggestive of a progressive cDC1 transcriptional change from healthy to 
tumor-bearing mice, with PanIN-draining as a transitional state (Fig. 3-3, A and B). Gene 
set enrichment analyses (GSEA) comparing tumor-draining and PanIN-draining ppLN 
cDC1s to those of healthy mice unveiled an upregulation of the proteasome degradation 
gene set (an aspect of antigen processing machinery that is upregulated during DC 
maturation) without an upregulation of genes encoding T cell polarizing cytokines such 
as Il-12b (Fig. 3-3, C-E). It has been demonstrated that cancer cells can induce DCs to 
produce immune suppressive factors like indoleamine 2,3-dioxygenase (IDO), actively 
enforcing adaptive immune tolerance206.  We therefore examined whether genes 
encoding known DC-secreted immune suppressive factors were altered in our system 
(Fig. 3-3F). Ido1 and Arg2 transcripts trended upwards in tumor-bearing mice but 
remained below five transcripts per million reads.  Therefore, it is unlikely that cDC1s 
here acquiring immune suppressive function over the course of KPC carcinogenesis, but 
are rather simply suboptimally maturing, coincident with inconsistent maturation marker 






cDC1-Mediated CD8+ T-cell Priming is Impaired in PanIN- and Tumor-Bearing Mice 
We next sought to evaluate cDC1 function in the context of our semi-maturation 
phenotype by way of T-cell priming in response to an antigen-specific challenge. Our 
group previously demonstrated a KPC-derived cell line (4662.V6ova) expressing chicken 
ovalbumin (OVA) gives rise to CD8+ T-cell-mediated spontaneous immunity when 
implanted subcutaneously into healthy mice190.  In order to evaluate this CD8+ T-cell 
priming event in the context of progressive carcinogenesis we subcutaneously implanted 
4662.V6ova cells into healthy, PanIN-bearing, and tumor-bearing mice.  We stained 
splenocytes from these mice for OVA-specific H-2Kb:SIINFEKL tetramer-positive CD8+ 
T-cells one week after implantation. The generation of OVA-specific CD8+ T-cells 
progressively declined in PanIN- and tumor-bearing KPC mice, consistent with our 
phenotype of semi-maturation (Fig. 3-4A). Notably, CD8+ T-cell priming in tumor-bearing 
KPC mice was so deficient that the condition was statistically indistinguishable from 
Batf3-/- mice, which lack cDC1s entirely197.  
Because of the potential for shared suppression between autochthonous KPC 
neoplasia and 4662.V6ova, we attempted to confirm our findings using a non-tumor 
vaccination strategy.  We vaccinated healthy, PanIN-bearing, and tumor-bearing mice 
with full-length OVA protein and the TLR9 agonist CpG (OVA/CpG). The total number of 
tetramer-positive T-cells was equivalent across all three groups, but the proportion of 
CD62L-CD44+ effector memory T-cells was decreased in PanIN- and tumor-bearing 
mice (Fig. 3-4B).  Additionally, expression levels of T-bet, Granzyme B, Ki-67, CTLA-4, 
and PD-1 were also decreased (Fig. 3-4C). While the precise quality of the deficiency 
appears to differ between our two priming models, the CD8+ T cell response in both the 
4662.V6ova and OVA/CpG settings is consistently defective in PanIN- and tumor-




cDC1 Abundance and Maturation Correlate with Increased Cytolytic Activity in 
Pancreatic Adenocarcinoma Patients  
We next quantified transcript abundance of XCR1, CLEC9A, CD86, HLA-DRA, 
GZMA, PRF1, and IFNG from pancreatic carcinoma samples in The Cancer Genome 
Atlas (TCGA-PAAD)207.  XCR1 and CLEC9A indicate cDC1s in humans and expression 
of these genes is used as an indication of cDC1 abundance208.  The geometric mean of 
GZMA and PRF1, known as the cytolytic index, has been previously experimentally 
validated as indicative of cytolytic activity209.  XCR1 and CLEC9A showed a strong 
positive correlation with cytolytic index (Fig. 3-10, A and B).  HLADRA and CD86, 
markers of DC maturation, also strongly correlated cytolytic index (Fig. 3-10, C and D).  
HLA-DRA and CD86 also moderately correlated with IFNG (Fig. 3-10, E and F). 
Therefore, in human PDAC tumors cDC1 abundance and maturation correlate with 
cytolytic activity, suggesting the relationships we uncovered in murine PDAC are also at 
play in human disease.  
 
cDC1 Abundance Declines as a Result of Apoptosis 
The decline of cDC1s may be due to decreased generation of precursor 
populations (decreased population “input”), increased death of mature populations 
(increased population “output”), or both.  To evaluate the role of precursor population 
generation we examined the frequencies of developmental populations in the bone 
marrow.  cDC1 progenitors consist of pre-cDCs, common DC progenitors (CDPs), and 
monocyte DC precursors (MDPs)202. MDPs have the potential to generate CDPs, 
monocytes, and monocyte-derived DCs, while CDPs give rise to pre-cDCs which include 
pre-cDC1s and pre-cDC2s. Pre-cDC1s then circulate to peripheral tissues where they 
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differentiate into cDC1s. We used flow cytometry to quantify MDPs, CDPs, and pre-
cDCs in the bone marrow of healthy, PanIN-bearing, and tumor-bearing mice (Fig. 3-
5A). Pre-cDC1s and pre-cDC2s were distinguished based on their expression of Ly6C 
and Siglec H210.  Bone marrow pre-cDC1s did not decline over the course of pancreatic 
oncogenesis (Fig. 3-5B). Pre-cDC1s in the peripheral blood were similarly unchanged 
(Fig. 3-5C). Ki-67 levels were evaluated in mesenteric lymph node (mLN) and iLN to 
determine whether cDC1 proliferation was altered.  Ki-67 levels were not significantly 
decreased in tumor-bearing mice compared to healthy controls, though Ki-67 transiently 
decreased in the iLNs of PanIN-bearing mice (Fig. 3-5D).  In accordance with these 
findings we conclude that our cDC1 paucity phenotype is not due to decreased 
generation of developmental precursors in the bone marrow, peripheral blood, or due to 
lower proliferation.  
We next evaluated whether systemic declines in cDC1 populations were driven 
by increased apoptosis (increased “output”).  We stained cDC1s for active cleaved 
caspase 3 and found that active cleaved caspase 3 increased progressively over the 
course of pancreatic carcinogenesis in both the ppLNs and iLNs (Fig. 3-6, A and B). 
Furthermore, transcriptomic analysis of ppLN cDC1s from PanIN- and tumor-bearing 
mice revealed enrichment for apoptosis genes including Apaf1, Bcl2l11, and Casp3 (Fig. 
3-6, C and D; Fig. 3-3C).  Therefore, we conclude that the decrease in cDC1 abundance 
in this model is driven by increased levels of apoptosis.   
 
CD40 Activation Rescues cDC1 Maturation 
The TNF-superfamily receptor CD40 is expressed on APCs and activation of this 
receptor by CD40 ligand (CD40L, found on activated CD4+ T-cells) licenses them to 
mature 127,211.  We sought, therefore, to reverse the cDC1 dysfunction in KPC mice 
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through CD40 activation.  We injected a KPC-derived cell line (6419.c5) subcutaneously 
into C57BL/6J mice and treated them with an agonistic monoclonal rat antibody (FGK45) 
against murine CD40 (Fig. 3-7A).  FGK45 administration resulted in decreased cDC1 
abundance in the tumor microenvironment (Fig. 3-7B).  We found that this cDC1 egress 
from the tumor was driven by corresponding migration to the tumor-draining lymph node, 
as shown by increased numbers of CD11cintMHC IIhi activated/migratory cDC1s (Fig. 3-
7C).  This migration was further corroborated by increased expression of the lymph 
node-homing receptor CCR7 in tumor-draining iLN CD11c+ cells (Fig. 3-7D).  FGK45 
treatment induced a broad upregulation of all evaluated maturation markers on cDC1s 
within the tumor, suggesting that cDC1 maturation was fully repaired (Fig. 3-7E). In the 
tumor-draining lymph node, FGK45 also increased the expression of CD40, CD86, and 
PD-L1 (Fig. 3-7F). In the spleen, expression of maturation markers also increased with 
the exception of MHC II, which declined (Fig. 3-7G).  
In order to rest whether priming function had also been rescued, tumor-bearing 
KPC mice were subcutaneously implanted with 4662.V6ova and treated with FGK45.  
Administration of FGK45 restored the generation of H-2Kb:SIINFEKL tetramer-positive 
CD8+ T-cells to levels seen in healthy mice (Fig. 3-7H). Thus, we conclude that CD40 
activation also reverses our T-cell priming deficiency phenotype.   
We next performed RNA sequencing tumor-draining lymph node cDC1s from 
mice bearing subcutaneous tumors +/- FGK45 treatment.  Principal component analysis 
of transcriptional variation revealed broad changes in cDC1s along PC1 following CD40 
agonist (Fig. 3-8A).  Differential gene expression analysis, however, revealed that 
treatment with FGK45 induced a significantly different transcriptomic signature 
depending on whether tumor was present (Fig 3-8B). GSEA comparing cDC1s in 
FGK45-treated vs. untreated tumor-bearing mice showed an induction of genes 
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associated with type II interferon signaling including Stat1 and Stat2 (Fig. 3-8, C-E). 
Thus, we demonstrate that cDC1 maturation and function are rescued by CD40 






In this study we elucidated the nature of cDC1 dysregulation during pancreatic 
cancer development in the KPC mouse model. We demonstrate for the first time that 
cDC1s are systemically dysregulated even prior to invasive tumor formation. This 
dysregulation was characterized by decreased cDC1 frequency, which was mediated by 
increased apoptosis.  cDC1 maturation was also dysregulated by way of a semi-
maturation phenotype, resulting in impaired T-cell priming.  In spite of the systemic and 
temporally early nature of this dysregulation, however, we demonstrate that semi-
maturation is reversible in vivo by a single-dose administration of CD40 agonist.   
One of our core findings was DC semi-maturation in KPC mice, evident from the 
earliest stages of malignant transformation.  DC semi-maturation is currently understood 
as the inconsistent upregulation of maturation markers on peripheral blood DCs 
associated with suboptimal T-cell priming204,205.  Here, we demonstrate that cDC1 semi-
maturation coincides with transcriptional upregulation of proteasomal degradation and 
antigen processing genes, absent the expected corresponding upregulation of T-cell 
polarizing cytokines.  We further show that this semi-mature phenotype was associated 
with poor CD8+ T-cell priming against OVA in the context of tumor OVA expression or 
OVA/CpG vaccination.  Further, this dysfunction was reversible through administration of 
CD40 agonist.  Our group has previously shown that CD40 agonist drives T-cell 
infiltration into KPC tumors and subsequently potentiates response to ICB in a Batf3-and 
IFNγ-dependent manner68,125,133.  We show in the present study that CD40 agonism 
induces an IFNγ response signature in cDC1s coincident with rescue of their maturation. 
An open question is whether this is due to direct ligation of CD40 on cDC1s as a result 
of IFNγ secreted by different CD40-expressing cell lineage211,212.  
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Given the critical role for cDC1s in driving CD8+ T-cell responses against cancer 
in humans, our murine findings have translational implications192,193,213.  Complementing 
those findings, we demonstrate that circulating cDC1s have decreased frequency in 
pancreatic cancer patients compared to healthy donors.  Furthermore, using expression 
of cDC1 markers XCR1 and CLEC9A191,208, we uncover a correlation between cDC1s 
within the tumor and cytolytic activity in pancreatic cancer patient samples in The Cancer 
Genome Atlas (TCGA-PAAD).  HLADR and CD86 were also strongly correlated with 
cytolytic index, complementing our murine findings regarding DC maturation122.  
It was also recently shown that cDC1 frequency in the human PDAC tumor 
microenvironment compared to non-small cell lung adenocarcinoma198.  Consistent with 
this finding, DC abundance has also been shown to progressively decline in human 
PanINs, consistent with our findings in KPC mice214.  
Finally, the reversal nature of the cDC1 dysregulation we uncover has particular 
applicability to promising agonist CD40 antibodies currently being evaluated as 
immunotherapy treatments in cancer patients74,138.  These trials will provide the 
opportunity to evaluate the effect of CD40 agonist administration on DCs in humans to 




Materials and Methods 
 
Human Subjects Research 
Blood samples from patients with advanced pancreatic cancer and healthy 
volunteers were collected and enriched using Ficoll centrifugation and cryopreserved in 
liquid nitrogen until analysis. Samples were obtained after informed consent and 
Institutional Review Board approval from the University of Pennsylvania. A total of 17 
patients (40 - 81 years old, males and females) with untreated advanced pancreatic 
ductal adenocarcinoma (two locally advanced, fifteen metastatic) and 10 healthy 
volunteers (54 - 75 years old) were included in the study. Patients with PDA and healthy 
volunteers were comparable (median age of patients 59, median age of healthy 
volunteers, 65; p=0.059 by two-tailed Student’s t test).  
 
Animal Studies 
All mouse experiments were done at the University of Pennsylvania Perelman 
School of Medicine, approved by the UPenn Institutional Animal Care and Use 
Committee, and performed in strict compliance with protocols 804666 & 804774. Mice 
were housed under pathogen-free conditions in a barrier facility. C57BL/6 mice were 
purchased from Jackson Laboratories or bred in-house. The size of each animal cohort 
was determined by estimating biologically relevant effect sizes between control and 







Subcutaneous Tumor Implantation 
Subcutaneously implanted KPC tumors were generated by injecting 3x105 cells 
in sterile DMEM into the right flank of female C57BL/6 mice unless otherwise specified. 
Cre/Cre and KPC mice were bred in-house. Tumor volume was calculated as greater 
diameter x smaller diameter2 . Mice were considered to have reached endpoint in 
survival analyses upon reaching a tumor volume of 500 mm3 .  
 
Antibody Experiments 
CD40 agonist studies were performed via a single intraperitoneal injection of 100 
μg of monoclonal CD40 agonistic antibody (InVivomAb FGK45) in 100 μl PBS.  
 
Vaccination Studies 
Vaccination of OVA/CpG was performed by subcutaneous injection of 200 μg 
endotoxin-free OVA (Invivogen vac-pova-100) + 10 μg endotoxin-free ODN1826 CpG 
(Invivogen tlrl-1826-1) in 200 μL PBS subcutaneously into the right flank.  
 
Tissue Processing and Cell Isolation 
Tumors and pancreas were dissected and minced in DMEM-F12 + 10% FBS at 
4C, then digested in DMEM-F12 with 1 mg/ml collagenase with protease inhibitor 
(Sigma-Aldrich C6079) for 30 min at 37C. Tissues were filtered through a 70 μm cell 
strainer, then a 40 μm cell strainer, with 9 ml FACS buffer (PBS w/ 0.2% BSA + 2 mM 
EDTA). Lymph nodes, spleens, and bone marrow were dissected and minced in RPMI + 
5% FBS at 4C, then digested in RPMI with 1 mg/ml collagenase (Sigma-Aldrich C5138) 
for 20 min at 37C. Spleens and bone marrow were subject to two rounds of RBC lysis 
using 1mL of ACK Lysis Buffer (Gibco A1049201). Samples were then filtered through a 
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40 μm cell straining and rinsed with 9 ml FACS buffer. Due to the small size of peri-
pancreatic lymph nodes (especially in healthy mice), peri-pancreatic lymph node 32 
samples were always pooled across all mice per experimental group to achieve 
sufficient cDC1 quantities for downstream analysis.  
 
Flow Cytometric Analyses 
All staining was performed in the dark. Tissue-derived cells were washed with 
PBS before viability stain with LIVE/DEAD Fixable Aqua (Invitrogen L34957) for 20 min 
at room temperature. Samples for DC analysis were then washed with FACS Buffer 
before being stained for immune markers CD45, CD64, F4/80, CD3, CD19, B220, 
NK1.1, Gr-1, I-A/I-E, CD11c, XCR1, SIRPα, CD103, CD11b, CD40, CD80, CD86, and 
PD-L1 for 30 min at 4C. Where appropriate, cDC1s were intracellularly stained for Ki-67 
and cleaved caspase 3 overnight at 4C. Samples for T-cell analysis were stained for 
immune markers CD45, CD3, CD8, CD4, H2Kb:SIINFEKL tetramer, TIM-3, LAG3, 
CTLA-4, PD-1, CD62L, and CD44 extracellularly for 30 min at 4C; and FOXP3, CTLA-4, 
Eomes, Granzyme B, Tbet, Ki-67, and IFN-γ intracellularly overnight at 4C. Bone 
marrow samples were stained extracellularly for Siglec H, c-Kit, CSF-1R, Flt3, SIRPα, I-
A/I-E, CD45, CD11b, Ly6C, CD11c, CD3, CD19, B220, NK1.1, and Gr-1 at 4C for 30 
min. To aid in obtaining an accurate quantification of cells in tumor samples, target 
events were normalized using CountBright Absolute Counting Beads (Life Technologies 
C36950) per manufacturer’s instructions. Samples were analyzed on a BD Biosciences 






RNA-Seq Analysis, Differential Gene Expression, and Gene Set Enrichment Analysis 
cDC1s were sorted using a BD Biosciences Aria II cell sorter with 100 μm nozzle 
into an Eppendorf tube with 350 μl Buffer RLT Plus at 4C using the gating strategy 
shown in Fig. 1A. RNA was isolated from sorted cDC1s using the Qiagen RNeasy Plus 
Micro Kit per manufacturer’s instructions. RNA purity and integrity were measured with 
an Agilent TapeStation prior to polyA selection and library construction followed by 
single-end 100 bp sequencing on an Illumina HiSeq4000 high-throughput sequencer at a 
depth of 20 million reads per sample by the UPenn Next-Generation Sequencing Core 
(NGSC). The curated RNA-seq analysis pipeline from bcbio-nextgen was used for 
downstream analysis (https://github.com/chapmanb/bcbio-nextgen). FASTQ files were 
checked for quality using FastQC and qualimap. Alignment was performed with STAR 
under default settings using the mm10 reference genome. Raw counts of gene 
transcripts were obtained from BAM files using featureCounts215. The resulting count 
matrix was then imported into R (version 3.6.1) and used as input to DESeq2 for 
normalization and differential gene expression analysis216. Salmon / Sailfish quasi-
alignment was used to normalize and quantify gene expression, and generate a 
transcripts per million (tpm) matrix to be used as input for gene set enrichment analysis 
(GSEA)217. Pathway and gene ontology analyses were 34 performed using GSEA and 
Gene Set Knowledgebase (GSKB), a curated functional genomics database for murine 
transcriptomes218. RNA-seq data have been submitted to and may be accessed at the 







The Cancer Genome Atlas 
RNA-seq datasets were downloaded with authorization for all patients with 
pancreatic ductal adenocarcinoma from The Cancer Genome Atlas (TCGA PAAD) on 
the National Cancer Institute’s Genomic Data Commons Portal207. 
 
Statistical Analysis 
Data points that were more than two standard deviations from the mean were 
removed as outliers. All statistical analyses of flow cytometry were performed using 
Graphpad Prism 7 or 8. Statistics in gene set enrichment analysis (GSEA) were 
performed using the gene set permutation setting within the Broad Institute GSEA 
software. Adjusted p-values (p-adj) below 0.05 and false discovery rate (FDR) q-values 
below 0.25 were considered statistically significant. Correlation analyses of TCGA PAAD 
gene expression were performed using Kendall’s tau rank correlation coefficient due to a 









Figure 3-1. cDC1 abundance declines systemically during pancreatic carcinogenesis. 
(A) Hematoxylin and eosin staining of healthy pancreas, PanIN-bearing pancreas, and 
pancreatic ductal adenocarcinoma. Arrows highlight ducts featuring mucinous 
metaplasia without dysplasia characteristic of pancreatic intraepithelial neoplasia 1A 
(PanIN 1A). All images are taken at 10X magnification. Scale bars denote 300 mm. 
(B) Flow gating strategy for CD45+CD64-F4/80-Lin-MHC II+CD11c+ conventional dendritic 
cells (cDCs) in a representative subcutaneously implanted KPC tumor. Lineage gate 
is comprised of CD3, CD19, B220, NK1.1, and Gr-1. 
(C-F) Quantification of cDC1s in the (C) pancreas/tumor, (D) peri-pancreatic lymph 
nodes (ppLN), (E) inguinal lymph nodes (iLN), and (F) spleen as a proportion of live cells 
and CD45+ cells. 
(G) Frequency of CD141+ cDC1s in peripheral blood of patients with untreated advanced 
PDA vs. healthy volunteers. 
Error bars indicate mean +/- SD. ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05 (one-way 
ANOVA with Tukey’s HSD post-test in C-F; Mann-Whitney test in G). Data shown in B-F 








Figure 3-2.  cDC1 maturation marker expression declines systemically during preinvasive 
neoplasia. 
Expression of maturation markers CD40, CD80, CD86, MHC II (I-A/I-E), and PD-L1 on 
cDC1s in the (A) pancreas/tumor, (B) peri-pancreatic lymph nodes (ppLN), (C) inguinal 
lymph nodes (iLN), and (D) spleen of healthy, PanIN-bearing, and tumor-bearing mice. 
Geometric MFIs shown. 
Samples were pooled across 3-6 mice per treatment group in B. Error bars indicate mean 
+/- SD. ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05 (one-way ANOVA with Tukey’s HSD 
post-test). Data shown are representative of four independent experiments with at least 








Figure 3-3.  cDC1 maturation is progressively impaired during pancreatic oncogenesis. 
(A) Principal component analysis (PCA) of cDC1s collected from healthy, PanIN-draining, 
and tumor-draining peri-pancreatic lymph nodes (ppLN). 
(B) Heatmap of differentially expressed genes by z-score across samples. 
(C) Top hits from gene set enrichment analysis (GSEA) comparing cDC1s from tumor-
draining vs. healthy ppLNs. 
(D) Enrichment plots of proteasome degradation and T-cell polarizing cytokine gene sets 
in cDC1s from GSEA shown in C. 
(E and F) Expression in transcripts per million reads (tpm) of genes encoding (E) 
inflammatory cytokines and (F) immune suppressive factors in cDC1s from healthy, 
PanIN-draining, and tumor-draining ppLNs. 
n=3 samples per group. Each sample consists of total RNA collected from 10,000 sorted 
ppLN cDC1s pooled from 3-6 mice. Error bars indicate mean +/- SD. ***p<0.001; *p<0.05 








Figure 3-4. cDC1-mediated CD8+ T cell priming is impaired in PanIN- and tumor-bearing 
mice. 
(A) Generation of H-2Kb:SIINFEKL tetramer-positive splenic CD8+ T cells in healthy, 
PanIN-bearing, and tumor-bearing mice seven days following subcutaneous 
implantation of 5x105 cells from clonal OVA-expressing KPC cell line 4662.V6ova. 
(B) Quantification of H-2Kb:SIINFEKL tetramer-positive splenic CD8+ T cells from healthy, 
PanIN-bearing, and tumor-bearing mice seven days following subcutaneous 
vaccination with 200 µg OVA + 10 µg CpG (OVA/CpG). 
(C) Activation/exhaustion marker expression in CD62L-CD44+ H-2Kb:SIINFEKL tetramer-
positive CD8+ T cells following vaccination with OVA/CpG. 
Error bars indicate mean +/- SD. ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05 (one-way 
ANOVA with Tukey’s HSD post-test). Data shown are representative of three 







Figure 3-5. cDC1 generation is unaffected by pancreatic neoplastic development. 
(A) Flow gating strategy for monocyte DC precursors (MDPs), common DC progenitors 
(CDPs), pre-cDCs, pre-cDC1s, and pre-cDC2s in RBC-lysed bone marrow suspension 
from a wild-type C57BL/6J mouse. Lineage gate consists of CD3, CD19, B220, NK1.1, 
and Gr-1. 
(B) Enumeration of MDPs, CDPs, pre-cDCs, pre-cDC1s, pre-cDC2s in the bone marrow 
of healthy, PanIN-bearing, and tumor-bearing mice. 
(C) Enumeration of pre-cDCs, pre-cDC1s, pre-cDC2s in peripheral blood. 
(D) Expression of Ki67 in cDC1s from the mesenteric lymph nodes (mLN) and inguinal 
lymph nodes (iLN) of healthy, PanIN-bearing, and tumor-bearing mice. 
Error bars indicate mean +/- SD. ****p<0.0001; **p<0.01; *p<0.05 (one-way ANOVA with 
Tukey’s HSD post-test). Data shown are representative of at least two independent 







Figure 3-6. cDC1 loss is driven by apoptosis. 
Percentage of (A) peri-pancreatic lymph node (ppLN) and (B) inguinal lymph node (iLN) 
cDC1s positive for expression of active cleaved caspase 3 in healthy, PanIN-bearing, 
and tumor-bearing mice. 
(C) Enrichment plot of apoptosis gene set in cDC1s from PanIN-draining vs. healthy 
ppLNs. 
(D) Expression of select genes in transcripts per million reads (tpm) from gene set shown 
in C. 
Samples pooled across at least four mice per treatment group in A. (C and D): Each 
sample consists of total RNA collected from 10,000 sorted ppLN cDC1s pooled across 3-
6 mice. Error bars indicate mean +/- SD. ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05 
(one-way ANOVA with Tukey’s HSD post-test in B. Data shown are representative of at 








Figure 3-7. CD40 activation repairs cDC1 maturation in KPC tumors. 
(A) Timeline of subcutaneous implantation of KPC cell line 6419.c5, administration of 
CD40 agonist (FGK45), and harvest of tissues for flow cytometric analysis. 
(B) Enumeration of cDC1s per live cells in subcutaneous KPC tumors from untreated and 
FGK45-treated mice. 
(C) Enumeration of CD11cintMHCIIhi migratory/activated cDC1s in the tumor-draining 
inguinal lymph node (iLN). 
(D) Expression of Ccr7 in CD11c+ cells purified from the iLNs of healthy mice and tumor-
draining iLNs of untreated and FGK45-treated mice bearing subcutaneously implanted 
KPC tumors. 
(E) Expression of maturation markers CD40, CD80, CD86, MHC II (I-A/I-E), and PD-L1 
on cDC1s from the tumors of untreated and FGK45-treated mice. 
Maturation marker expression on cDC1s from the (F) tumor-draining iLN and (G) spleen 
of healthy mice, untreated tumor-bearing mice, and FGK45-treated tumor-bearing 
mice. 
(H)  Enumeration of H-2Kb:SIINFEKL tetramer-positive splenic CD8+ T cells from healthy 
mice, untreated tumor-bearing KPC mice, and FGK45-treated tumor-bearing KPC 
mice twelve days following subcutaneous implantation of OVA-expressing clonal KPC 
cell line 4662.V6ova. 100 µg FGK45 was administered on day 9 post-implantation. 
Error bars indicate mean +/- SD. ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05 (two-tailed 
Student’s t-test in B, C, E; one-way ANOVA with Tukey’s HSD post-test in D, F, G, H). 








Figure 3-8. CD40-driven cDC1 maturation is associated with an IFNγ response signature. 
(A) Principal component analysis (PCA) of inguinal lymph node (iLN) cDC1 transcriptomes 
in the presence or absence of subcutaneously implanted KPC tumor, either treated or 
untreated with CD40 agonist (FGK45). 
(B) Heatmap comparing expression of differentially expressed genes across samples, 
scaled by z-score. 
(C) Top hits from gene set enrichment analysis (GSEA) of tumor-draining iLN cDC1s from 
FGK45-treated vs. untreated mice. 
(D) Enrichment plot of type II interferon response gene set from GSEA shown in C. 
(E) Expression of Stat1 and Stat2 in transcripts per million reads (tpm) from gene set 
shown in D. 
n=3 samples per group. Each sample consisted of total RNA collected from 10,000 sorted 
iLN cDC1s pooled from five mice per group. Error bars indicate mean +/- SD. **p<0.01; 








Figure 3-9. cDC1 abundance only declines based on cell fractions during pancreatic 
carcinogenesis. 
(A-D) Tissue weight, cDC1 number per organ, and cDC1 number per mg tissue in the (A) 
pancreas/tumor, (B) peri-pancreatic lymph node, (C) inguinal lymph node, and (D) spleen 
from healthy, PanIN-bearing, and tumor-bearing mice. 
****p<0.0001; *p<0.05 (one-way ANOVA with Tukey’s HSD post-test). Data shown are 








Figure 3-10. cDC1 abundance and maturation are associated with increased cytolytic 
activity in human pancreatic ductal adenocarcinoma. 
Correlation analyses of (A) XCR1 gene expression and cytolytic index (CTL), (B) CLEC9A 
gene expression and cytolytic index, (C) HLA-DRA gene expression and cytolytic index, 
(D) CD86 gene expression and cytolytic index, (E) HLA-DRA gene expression and IFNG 
gene expression, and (F) CD86 gene expression and IFNG gene expression in tumors of 
patients from the Cancer Genome Atlas with pancreatic ductal adenocarcinoma (TCGA-
PAAD). 
n=182 total patients in TCGA-PAAD. Regression line, 95% confidence interval, Kendall’s 
tau rank correlation coefficient, and associated p-value shown for all correlation analyses. 




CHAPTER 4 – SUMMARY, DISCUSSION, AND FUTURE 
DIRECTIONS 
 
The goal of my thesis work was to contribute to the foundation of the next 
generation of cancer immunotherapies.  ICB is a tremendous breakthrough but it is clear 
at this point that it is not an appropriate treatment for all cancers.  In accordance with the 
Cancer Immunity Cycle (CIC) model, it is posited that while these agents are quite 
effective at reversing T-cell dysfunction, they only address the subset of cancers that are 
dysregulated at that singular stage.  Most patients, however, have disease in which the 
CIC is dysregulated in at least one other stage.  This necessitates studying the basic 
immune dysregulation of ICB-resistant cancers such as PDAC.   
Using PDAC as a model, my graduate work has touched on nearly every step of 
the CIC.  Previous work during my time in our lab (and in fact my preliminary 
examination for advancement to candidacy) studied the role of tumor antigens and 
antigen release (Figure 1-2.1, 2)68,108,134.  In chapter 3, I characterize a mechanism of 
priming dysfunction (Figure 1-2.3) and demonstrate that, analogous to T-cell dysfunction 
being reversed by ICB, priming dysfunction can be reversed through activation of CD40 
by an agonistic mAb.  In chapter 2, I elucidate a T-cell trafficking dependency (Figure 1-
2.4) whose loss abrogates the therapeutic benefit of CD40/ICB. Furthermore, in chapter 
2 I confirm that CD40 agonist potentiates PDAC to ICB, illustrating that while priming is a 
core deficiency in PDAC anti-cancer immunity, T-cell dysfunction also concurrently 
occurs (Figure 1-2.5).  In this manner, I demonstrate in my collective graduate work that 
PDAC is characterized by deficiencies at multiple stages of the CIC.  As such, I provide 
evidence that immunotherapeutic strategies to treat PDAC – and potentially by extension 
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other such difficult-to-treat “cold” tumors – will necessarily require interventions at 
multiple stages of the CIC to reverse those deficiencies.     
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Summary, Discussion, and Future Directions of Chapter 2 
Our group previously demonstrated that CD40 agonist and ICB combination 
therapy induces durable long-term regressions and cures in a mouse model of 
pancreatic cancer132.  Key dependencies of CD40/ICB treatment efficacy include cDC1s, 
IFNγ, and both CD8+ and CD4+ T-cells.  Interestingly, memory rechallenge response in 
these conditions was only dependent on CD4+, but not CD8+ T-cells.  The efficacy of 
this combination immunotherapy was encouraging, but mechanisms remained elusive.  
Notably, the mechanisms of tumor T-cell trafficking – the link between priming and 
peripheral T-cell dysfunction – and the disproportionate importance of CD4+ T-cells were 
unexplained.  In order to answer these questions in a highly dimensional and unbiased 
manner, we took advantage of newly developed single-cell sequencing technologies that 
allowed us to study the how the TME evolves in response to CD40/ICB therapy in 
unprecedented detail.  We uncovered a striking upregulation of the chemokine CCL5 
across a range of intratumoral immune populations in response to CD40/ICB and 
demonstrate that loss of CCL5 blunted response to therapy.  We show that CCL5 is 
necessary for CD4+, but not CD8+ T-cell infiltration in response to CD40/ICB therapy 
and that the trafficking of CD4+ T-cells to the tumor is mediated by their expression of 
CCR5.   
The current understanding of CCL5 in cancer posits that the chemokine is 
generally a negative prognostic marker and attracts FoxP3+ T-regulatory cells and 
tumor-associated macrophages to the tumor144,147,219,220.  Consistent with these prior 
studies, we observe fewer T-regulatory cells in the tumors of CCL5 KO mice.  When 
CD40 agonist is administered, however, the primary effect of CCL5 in our system was 
the promotion of CD4+ (FoxP3-) T-cell infiltration into the tumor.  CCL5 blockade also 
108 
 
increased the expression of CD39, LAG-3, and PD-1 in intratumoral CD4+ T-cells with 
no effect on CD8+ T-cells, suggesting a role for CCL5 in maintaining CD4+ T-cell 
activation in the tumor microenvironment. Thus, we show a strikingly different role of 
CCL5 in tumor immune biology following CD40 agonism.  Rather than attracting pro-
tumor T-regulatory cells at baseline, CCL5 plays a critical anti-tumor role in FoxP3- 
CD4+ T-cell chemotaxis following CD40 agonism. Additionally, in at least one other 
model CCL5 derived from the tumor cells has been shown to indirectly enable 
chemotattraction of CD8+ T-cells by way of CXCL9146.  In our system, however, CCL5 
did not modulate CD8+ T-cell infiltration and was not produced by any of the non-
hematopoietic tumor components. This differential effect is particularly interesting given 
the comparable expression levels of CCR5 between CD4+ and CD8+ T-cells in our 
system.  It may be that different homing receptors are functionally more important in 
different T-cell subsets than others; for example, CCR5 dominating CD4+ T-cell homing 
and CXCR3 dominating CD8+ T-cell homing.  Consistent with this concept, CCR5 
blockade can ameliorate graft-versus-host disease, which is understood to be a 
predominantly CD4+ T-cell-mediated disease151–154,221.  In our system, the CXCR3 ligand 
CXCL9 was also upregulated in macrophages after CD40/ICB treatment (Table 2-1).  In 
the initial phase of this project I generated preliminary data (not shown) which 
demonstrated that blocking CXCL9 caused no change in therapeutic efficacy of the 
combination immunotherapy.  Loss of the chemokine, however, may well have resulted 
in decreased CD8+ T-cell infiltration into the tumor, and merits further inquiry.  
Alternately, there may be additional chemokine-chemokine receptor interactions at play 
in CD8+ T-cells acting in opposition to the effect of CCL5-CCR5 in this system or 
differentially modulating T-cell egress from the tumor.  Our data, therefore, highlight the 
context-dependent nature of CCL5 in tumor immunology.   
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While we predict that the effect of CCL5 in this system is source-agnostic, it may 
be that cells beyond the anti-tumor myeloid lineages meaningfully contribute to this 
phenotype.  In terms of CCL5 derived from CD8+ T-cells or cDC1s, there were far fewer 
of these cells than macrophages in the PDAC tumors at baseline (Figure 2-8) and 
neither lineage increases the proportion of cells expressing CCL5 as a function of 
CD40/ICB treatment.  Nevertheless, both lineages are strong producers of CCL5 at the 
cell-by-cell level and could contribute to this phenotype on that basis.  Therefore, an 
important future direction to understand the specific effect of myeloid-derived CCL5 
would be testing CD40/ICB in myeloid-specific CCL5 KO systems.  Additionally, the 
injection of CCL5 intro tumors in an attempt to rescue CD40/ICB efficacy in CCL5 
knockout mice would be valuable.   
If the intratumoral injection of CCL5 (or any other artificial local amplification of 
CCL5 within the tumor) does in fact augment CD40/ICB therapy this strategy has clinical 
potential – for example through combination with a CCL5-secreting oncolytic virus.  Our 
data (and others’ 144,145,147,220) would support caution, however, as CCL5 at baseline in 
untreated tumors is associated with T-regulatory cell attraction and CD8+ T-cell 
exclusion.  Any potential strategy including CCL5 to amplify CD40/ICB therapy, 
therefore, should take care to amplify intratumoral CCL5 only after treatment.  
Furthermore, given the deleterious effect on CD4+ T-cell infiltration by CCR5 loss, care 
should be taken when considering CD40/ICB as a treatment for patients on CCR5 
inhibitors.  Finally, as the promising combination of CD40 agonist and ICB agents is 
advanced in pancreatic cancer patients our findings support that CCL5 could be explored 
as a biomarker for clinical response138.  
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Summary, Discussion, and Future Directions of Chapter 3 
ICB-resistant immunologically “cold” tumors are characterized by a paucity of 
intratumoral T-cells.  It could be that these tumors exclude T-cells by evading pre-
existing T-cell immunity.  T-cells are often excluded from the earliest stages of disease, 
however, and no evidence of immunoediting has been observed in these tumors189,190.  
These findings are consistent with defective T-cell priming instead of evasion of existing 
T-cell immunity74.  In chapter 3, we discover using the KPC mouse model of a “cold” 
tumor that this priming deficiency is due to a systemic and progressive dysregulation of 
cDC1s from the very earliest stages of oncogenesis.  This dysregulation is characterized 
by a paucity of cDC1s due to increased cDC1 apoptosis.  Furthermore, we demonstrate 
that this priming defect can be reversed in vivo by the administration of CD40 agonist.   
A decline in cDC1 abundance has previously been reported in tumor-bearing 
KPC mice222. However, the conclusion provided in that study contrasts with our findings. 
While Meyer et al. attribute decreased cDC1 abundance to impaired bone marrow cDC1 
generation caused by G-CSF-mediated suppression of IRF8, we observe that cDC1 
generation is unaffected during pancreatic carcinogenesis. Rather, we focus on very 
early events in cDC1 dysfunction and show prominent apoptosis and semi-maturation of 
cDC1s in PanIN-bearing mice that have not previously been reported.  A potential 
explanation for the contrasting findings may be technical differences in KPC models, but 
future experimentation will be necessary to resolve the discrepancies between these two 
studies.   
Systemic DC dysfunction has been reported in the past in advanced-stage 
cancer patients223–225. Although cancer patients generally do not suffer opportunistic 
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infections like patients with AIDS, there is evidence for cancer patients having 
immunodeficiencies. One example is the higher risk of Varicella zoster, a classically T 
cell-controlled pathogen, across multiple liquid and solid malignancies compared to age-
matched controls226. Pancreatic cancer patients also exhibit abnormalities in T cell 
subsets and activation at the time of diagnosis prior to therapy227. It seems likely that 
progressive cancer itself reflects - to a greater or lesser extent – failed immune 
surveillance, even in pancreatic cancer228. With these new insights into cDC1 
dysfunction in KPC mice, it will be important to examine T cell immunity in cancer 
patients more deeply with a mindful eye towards clinical and immune phenotypes in the 
future. 
That the priming deficiency we characterized begins so early in oncogenesis, yet 
remains reversible by CD40 agonist throughout the entire course of malignancy, is 
remarkable.  While CD40 agonist reverses the priming deficit and drives T-cells into the 
tumor, as a monotherapy it does not induce meaningful tumor regressions without the 
addition of ICB 132.  The insufficiency of CD40 agonist monotherapy and subsequent 
response to CD40/ICB indicates that T-cell dysfunction is also likely a feature of PDAC, 
though one downstream of dysregulated T-cell priming.   
CD40 agonist rescued cDC1 maturation, but not frequency.  Flt3L administration 
was recently shown to synergize with CD40 agonist to increase cDC1 numbers198, a 
finding we were able to replicate in our system (data not shown).  The addition of Flt3L 
to CD40/ICB therefore has the potential to augment therapeutic response and the 
combination therapy of all four immunomodulatory agents should be explored in future 
experiments.   
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We demonstrated that cDC1 paucity in our system is driven by increased 
apoptosis of that cell lineage.  Although the data are not included in this thesis, we have 
since shown that this apoptosis is driven by IL-6, which is elevated systemically.  As IL-6 
inhibitors such as tocilizumab are already used in the clinic, a potential role for these 




The Next Generation of Immunotherapies 
ICB agents currently serve as the backbone of cancer immunotherapeutics and a 
considerable amount of work has been focused recently on converting ICB-resistant 
tumors to ICB-responding tumors (“hot” vs “cold” paradigm see Figure 1-1).  
Understanding the basic immunological pathways that underlie intrinsic and acquired 
resistance to these agents is critical to developing strategies to counteract those 
pathways. 
One such resistance mechanism is the efficient presentation of tumor antigens 
on MHCI by tumor cells.  A CRISPR screen study recently identified that PD-1 treatment 
placed a treatment pressure on tumors that selected for the loss of MCHI antigen 
presentation genes229.  Indeed, tumor loss of MHCI appears to be a considerable feature 
of ICB-resistant “cold” tumors230–232.  Strategies that result in the upregulation of MCHI 
therefore are attractive for sensitizing (or re-sensitizing) “cold” tumors to ICB.  For 
example, the CD4/6 inhibitor abemaciclib was recently shown to upregulate tumor MHCI 
antigen presentation machinery, drive tumor T-cell infiltration, and ultimately sensitize a 
model of breast cancer to PD-L1 inhibition233.  MHCI upregulation is also associated with 
the anti-cancer mechanism of oncolytic viruses.  One of the effects of viral infection is 
the production of IFNγ, which results in the upregulation of MHCI.  Accordingly, oncolytic 
viruses have been shown to augment ICB treatment in “cold” tumors234.  Similarly, 
Stimulator of Interferon Genes (STING) agonists induce (as the name would suggest) 
robust IFN signaling and have been shown to synergize with ICB235.  CD40 agonist 
treatment is also IFNγ-dependent, although notably independent of STING132,133. 
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MHCI modulation is an important ICB-resistance mechanism, but only one way in 
which tumor cell-intrinsic mechanisms mediate immunosuppression.  There is a recent 
appreciation for the effects that oncogenes have on the immune character of their local 
microenvironment.  For example, cMYC has been shown to drive macrophage 
recruitment to the tumor236, limit infiltration of NK and T-cells into the tumor237, and drive 
tumor expression of immunosuppressive PD-L1 and CD47238.  Much less is known about 
the immunosuppressive effects of KRAS, (mutated in 90+% of PDAC tumors239) 
although mutant KRAS has been shown to drive tumor production of GM-CSF which 
recruits neutrophils240.  Given the characteristic immunosuppression of PDAC tumors 
and the remarkable penetrance of mutated KRAS in that disease it seems likely that 
further study of the “KRAS Immunosuppressome” will yield additional potential targets.  
Since KRAS activates half a dozen downstream pathways and is itself is very difficult to 
drug (recent development of specific G12C KRAS mutation inhibitors aside241) it may 
behoove researchers to study instead the discrete effects of those downstream signaling 
pathways242.   
With respect to the future of the CD40/ICB treatment described in this thesis, 
while the treatment effect is quite impressive in the context of highly lethal disease 
PDAC, there is still room for considerable improvement.  Subcutaneously implanted 
PDAC, while an important model that recapitulates the TME of the human disease, 
shows consistently favorable responses relative to the KPC mouse model.  Additionally, 
most human PDAC diagnoses are made in late stage disease often including 
metastasis, which our treatment model did not recapitulate.   Clearly, therefore, the 
rational combination of additional immunomodulatory agents on top of the CD40/ICB 
backbone merits exploration.   
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Two such targets are T-cell immunoreceptor with Ig and ITIM domains (TIGIT)71 
and V-domain Ig suppressor of T-cell activation (VISTA)243.  TIGIT is expressed on T- 
and NK-cells while VISTA is expressed on immune cells more broadly, and each is a 
checkpoint receptor that negative regulates anti-tumor immunity244–248.  Our group 
previously published that TIGIT and VISTA expression within the tumors of PDAC 
patients are associated with the cytolytic index and predictive of survival249.  Early in my 
thesis I generated data (not shown) that CD40 agonist induces the upregulation of TIGIT 
and VISTA within subcutaneously implanted PDAC tumors.  While preliminary data was 
suggestive that TIGIT blockade did not add survival benefit on top of CD40 alone, it may 
be that PD-1 and/or CTLA-4 are also required to potentiate TIGIT blockade therapeutic 
benefit.  I was unable to study VISTA blockade at the time due to reagent limitations but 
further exploration of both pathways in PDAC is merited.    
The development of additional immunomodulatory agents brings us closer to the 
tantalizing potential to precisely engineer immune responses and the ability to 
orchestrate bespoke therapies specific to the characteristics of the cancer (or other 
immunological insult) of the patient at hand.  That is truly the promise of personalized 
medicine.  But precise orchestration requires optimal sequencing, and optimizing 
sequencing becomes exponentially more difficult with each additional agent.  Our 
group’s experience optimizing the three agents in CD40/ICB is an illustration.  Alex 
Morrison demonstrated that the same number of ICB doses leads to better outcomes if 
the first dose is given three days before CD40 agonist is administered.  We hypothesize 
this is due to CTLA-4 inhibition removing a negative regulator of T-cell priming at the 
point in time where the priming deficiency native to PDAC is reversed.  The sequencing 
of immunomodulatory cocktails containing 2-3 drugs may still be optimized using brute 
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force combinatorial experiments but moving beyond that magnitude necessitates 
hypothesis-driven experimentation based on our understanding of the basic immunology 
underpinning these agents.  This same principle applies to clinical trials – brute force 
testing of every possible combination is untenable based on the number of patients who 
participate in clinical trials250.  As such, testing agents in rational combinations based on 
the underlying biology is the superior approach.   
The translational success of ICB is a remarkable success story, predicated on 
many years of careful basic research into the mechanisms of cancer immunology.  In 
fact, the curative promise of immunotherapeutic strategies as demonstrated by the 
transformative clinical impact of these agents is precisely what drew me to become an 
immunologist.  My thesis work offers some insights into those cancers with a more 
complicated immune dysregulation that may inform the next generation of 
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